CN101534855A - Vaccine - Google Patents

Vaccine Download PDF

Info

Publication number
CN101534855A
CN101534855A CNA200780041465XA CN200780041465A CN101534855A CN 101534855 A CN101534855 A CN 101534855A CN A200780041465X A CNA200780041465X A CN A200780041465XA CN 200780041465 A CN200780041465 A CN 200780041465A CN 101534855 A CN101534855 A CN 101534855A
Authority
CN
China
Prior art keywords
vaccine
type
antigen
antigen unit
ipv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA200780041465XA
Other languages
Chinese (zh)
Other versions
CN101534855B (en
Inventor
H·德亨普丁纳
M·迪谢纳
A·玛丽
M·索恩沃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0625593A external-priority patent/GB0625593D0/en
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Priority claimed from PCT/EP2007/059390 external-priority patent/WO2008028956A1/en
Publication of CN101534855A publication Critical patent/CN101534855A/en
Application granted granted Critical
Publication of CN101534855B publication Critical patent/CN101534855B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The standard dose of polio vaccines contains 40 D-antigen units of inactivated poliovirus type 1 (Mahoney), 8 D-antigen units of inactivated poliovirus type 2 (MEF-1), and 32 D-antigens units of inactivated poliovirus type 3 (Saukett). The present invention teaches that reduced doses of inactivated poliovirus can maintain an adequate or improved level of protection against polio.

Description

Vaccine
Invention field
The present invention relates to the vaccine field that is used to guard against poliomyelities, relate in particular to be used to guard against poliomyelities, the combined vaccine of diphtheria, tetanus and pertussis disease.
Background technology
For make the required immune time of the protection of giving anti-multiple pathogen minimum, reduce the administration cost and increase receptance and coverage rate, combined vaccine (it provides the protection of anti-multiple pathogen) is very ideal.The antigenic competition of many data records (or interference) phenomenon makes the exploitation of multicomponent vaccine complicated.Antigen disturbs and to be meant to observe and to use multiple antigen and often cause antigenicly replying replying when using separately with respect to these antigen and reducing at some.
Known combined vaccine can prevent bordetella pertussis (Bordetella pertussis), clostridium tetani (Clostridium tetani), diphtheria corynebacterium (Corynebacterium diphtheriae), poliovirus (IPV) and/or hepatitis B virus and/or Type B haemophilus (Haemophilus) infection (referring to for example WO 93/24148, WO97/00697 and WO2000/030678) with optional prevention deactivation.
After research for many years, the poliomyelitis vaccine that is regarded as effective standard dose in the vaccine field comprises the deactivation 1 type poliovirus (Mahoney) of 40D antigen unit, the deactivation 2 type polioviruses (MEF-1) of 8D antigen unit and the deactivation 3 type polioviruses (Saukett) of 32D antigen unit (Infanrix-IPV for example TM).
The inventor finds that surprisingly the IPV that reduces dosage can keep poliomyelitis protection level enough or that improve.This vaccine has important advantage, is included as the individuality that needs this vaccine the more ability of the IPV vaccine of high dose is provided.
Summary of the invention
Therefore, the invention provides the IPV vaccine (it can only contain the IPV component maybe can contain IPV component and other antigen) of various reduction dosage.
Therefore, the invention provides on the one hand a kind of IPV vaccine of the present invention, it comprises dosage greater than 10D antigen unit and less than the deactivation 1 type poliovirus of 20D antigen unit (for example 11,12,13,14,15,16,17,18 or 19D antigen unit).
In one embodiment, the invention provides a kind of IPV vaccine of the present invention, it comprises the deactivation 3 type polioviruses that dosage is 8-20D antigen unit (for example 8,9,10,11,12,13,14,15,16,17,18,19 or 20D antigen unit).
In another embodiment, the invention provides a kind of IPV vaccine of the present invention, it comprises the deactivation 2 type polioviruses that dosage is 2-4D antigen unit (for example 2,3 or 4D antigen unit).
In another embodiment, the invention provides a kind of IPV vaccine of the present invention, the pertussis vaccine that it also comprises diphtheria toxoid and/or tetanus toxoid and/or adopts deactivation full cell Pw vaccine or acellular pertussis antigen form.
On the other hand, the invention provides a kind of IPV vaccine of the present invention, it is the DTP-IPV combined vaccine that does not contain thimerosal, and comprising dosage is the deactivation 1 type poliovirus of 10-36D antigen unit.
In another embodiment, the invention provides the DTP-IPV combined vaccine that a kind of the present invention does not contain thimerosal, it comprises the deactivation 2 type polioviruses that dosage is 2-7D antigen unit (for example 5,6 or 7D antigen unit).
In another embodiment, the invention provides the DTP-IPV combined vaccine that a kind of the present invention does not contain thimerosal, it comprises the deactivation 3 type polioviruses that dosage is 8-29D antigen unit (for example 21,22,23,24,25,26,27,28 or 29D antigen unit).
In another embodiment, vaccine of the present invention can also comprise and is selected from one or more antigens of following group: hepatitis B surface antigen, b type hemophilus influenza (Haemophilus influenzae) antigen, A type meningococcus (Neisseria meningitidis) antigen, C type hitchens and Hansen antigen, W type hitchens and Hansen antigen, Y type hitchens and Hansen antigen, Type B meningococcus bleb or antigen, hav antigen and salmonella typhi ((Salmonella typhi)) antigen is especially from the capsular saccharides of described antibacterial.
Also provide the present invention to prepare the method for vaccine.
Definition
Term " vaccine " optionally can be replaced with " immunogenic composition ", and vice versa.
" D antigen unit " (also be called " iu " or IU): the D antigen form of poliovirus is induced the protectiveness neutralizing antibody.The total D antigen unit that records in the initial IPV antigenic type is not adsorbed at each in the D antigen unit that this paper mentions (for example in vaccine of the present invention) before the preparation of whole vaccine, described whole vaccine is added in the per capita dose of preparation vaccine (common final volume is 0.5mL).The reliable method of measuring D antigen unit is well known in the art, and is for example open by European Pharmacopoeia (European Pharmacopoeia).For example, the ELISA experimental measurement D antigen unit that can describe according to embodiment 1 (" the D antigen by ELISA is quantitative ") hereinafter.European Pharmacopoeia provides test specimen (European Pharmacopoeia Biological ReferencePreparation (European Pharmacopoeia reference biomolecule goods), available from Ph.Eur.Secretariat, for example CodeP 216 0000), so that between manufacturer with this methodological standardization (Pharmeuropa SpecialIssue, Bio 96-2).Therefore D antigen unit value is being known in the art.
The term " dosage " of this paper " the applied once amount of vaccine of the present invention normally, it is injection shot normally.Typical people's dosage is 0.5mL.Certainly in the vaccine administration scheme, can use various dosage.
Term " IPV " or the vaccine that comprises these components are intended to represent that poliovirus 1 type of deactivation is (for example as the preferred Mahoney that uses herein, or the Brunhilde of Statens Serum Institut sale, be called DiTeKiPol), 2 types (for example MEF-1) or 3 types (for example Saukett), or the combination of the two or all three kinds of these types.The example that is used for the object of the invention complete (or standard) dosage (being respectively the 40-8-32D of 1,2 and 3 type IPV) IPV vaccine can be
Figure A200780041465D0013134637QIETU
(GSK Biologicals S.A.).Therefore, when the X% that describes the IPV standard dose at this paper was present in vaccine of the present invention, its expression equals 40,8 and/or the 32D antigen unit (measuring) of 1,2 and/or 3 type IPV respectively in each initial IPV antigenic type the D antigen unit of X% was formulated in the described vaccine of every dosage.
Term " lipopolysaccharide " (LPS) (LOS) can exchange with " fat oligosaccharide ".
In this description from start to finish, term " sugar " expression polysaccharide or oligosaccharide, and comprise the two.Capsular saccharides antigen can be the total length polysaccharide; or it can expand to the known antibacterial in vaccine field ' fractionated sugar (sized-saccharides) ' and ' oligosaccharide ' (its natural recurring unit with low quantity; or it is the polysaccharide that reduces aspect big or small for the ease of handling, but still can induce the immunne response of protectiveness in the host) (referring to for example EP 497525).
The term of this paper " nucleic acid " comprises strand or double stranded DNA (DNA), or strand or double stranded RNA (RNA), or its mixture.
Term in vaccine scope of the present invention is intended to represent one or more antigens from this pathogen from " component " of pathogen or " giving the component to this pathogen protection ".
The term of this paper " probably " or " approximately " are intended to represent designated value ± 10%, but should meet effective range.
The accompanying drawing summary
Fig. 1. contain the development of relative effectivenes (RP) of the DTPwSF-HB-IPV " preparation method 3 " of IPV dosage.
Detect the effectiveness of the preparation " preparation method 3 " that reduces dosage IPV in vivo, (Poliorix preparation and DTPaIPVHB) compares with the reference preparation.RP according to 100%, 50%, 25% and 12.5% dosage measurement IPV of standard I PV dosage (is 40/8/32D antigen unit for 1/2/3 type).
The flow chart of Fig. 2 .DTPwSF-HB-IPV preparation relative effectivenes (RP) development.
Detect the effectiveness of the reduction dosage IPV of two kinds of preparations " preparation method 3 " and " preparation method 4 " in vivo, (Poliorix preparation and DTPaIPVHB) compares with the reference preparation.Compare with the placebo that only contains 25%IPV, detect the RP that contains 25% standard I PV dosage (is 40/8/32D antigen unit for 1/2/3 type) " preparation method 3 " and " preparation method 4 ".
Fig. 3. at beginning and the relative effectivenes of 1,2 and 3 type IPV 8th month the time.
Detect IPV relative effectivenes [with respect to DTPaHBIPV (Pediarix) (Fig. 3 a) or Poliorix (Fig. 3 b)] determining whether the Hib component influences IPV and render a service, and estimate IPV stability in time under the different IP V dosage condition.
Describe in detail
The invention provides a kind of vaccine (for example combined vaccine), it comprises the antigen from poliovirus (IPV) and optional corynebacterium diphtheriae (D), clostridium tetani (T), Bordetella pertussis (P) or hepatitis B.
Antigen of the present invention
The IPV vaccine component
Vaccine of the present invention can be comprised of 1 type IPV or 2 type IPV or 3 type IPV, or is comprised of 1 and 2 type IPV, or is comprised of 1 and 3 type IPV, or is comprised of 2 and 3 type IPV, or is comprised of 1,2 and 3 type IPV.
The method for preparing inactivated poliovirus (IPV) is well known in the art. In one embodiment, just common such as vaccine this area, IPV comprises 1,2 and 3 types, can be the usefulness formalin-inactivated the picogram polio vaccine (referring to for example, the people such as Sutter, 2000, Pediatr. Clin.North Am.47:287; Zimmerman ﹠ Spann 1999, Am Fam Physician 59:113; The people such as Salk, 1954, Official Monthly Publication of the American Public Health Association 44 (5): 563; Hennesen, 1981, Develop.Biol. Standard 47:139; Budowsky, 1991, Adv.Virus Res.39:255).
In one embodiment, IPV is non-adsorbable (if for example there are other components, with before these components are mixed). In another embodiment, IPV component of the present invention can be adsorbed onto aluminium salt such as aluminium hydroxide (if for example there are other components, with before or after these components are mixed). In another embodiment, IPV component of the present invention can be adsorbed onto aluminium salt such as aluminum phosphate. In another embodiment, the IPV component can be adsorbed onto the mixture of aluminium hydroxide and aluminum phosphate. If absorption, resulting mixture can be adsorbed separately or adsorb together to one or more IPV components. Can stablize IPV by the specific dry run of describing such as WO2004/039417.
Poliovirus can be grown in cell culture. Described cell culture can be VERO clone or PMKC, and it is the continuous cell line that is derived from the monkey kidney. Can in microcarrier, cultivate easily the VERO cell. Before the virus infections and during cultivate the VERO cell and may need to use raw material from ox such as calf serum, and this raw material should be available from the source that does not have bovine spongiform encephalitis (BSE). Cultivation may also relate to such as materials such as lactalbumin hydrolysates. After propagation, can utilize technology purified virus particles such as ultrafiltration, diafiltration and chromatography. Before using to the patient, virus must be inactivated, and this can be by realizing with formaldehyde treated.
Virus is propagation, purifying and deactivation separately, then it is mixed to get concentrated original mixture and is used for the IPV vaccine use, or add the vaccine that the diphtheria of absorption and lockjaw antigen and pertussis component are used for comprising DTPw-IPV or DTPa-IPV to.
Antigen in the vaccine of the present invention will exist with " immune effective dose ", namely use described amount (with single dose or as the form of the part of successive doses) to individuality and can effectively treat or prevent disease. Dosage treatment can be single dose scheme or multiple dose scheme (for example comprising booster).
The standard dose of polio vaccine tends to comprise the deactivation 1 type poliovirus of 40D antigen unit now, the deactivation 2 type polioviruses of 8D antigen unit, and the deactivation 3 type polioviruses of 32 D antigen units (Infanrix-IPV for exampleTM)。
But the inventor is surprised to find that and can uses the IPV that reduces dosage to obtain good immune response. In one embodiment, IPV vaccine dose of the present invention can comprise the 1 type IPV (for example 11-32,12-28,13-24,14-20 or 15-19D antigen unit) of 10-36D antigen unit. In another embodiment, IPV vaccine dose of the present invention can comprise the 1 type IPV that dosage is 10-20 D antigen unit, or dosage is greater than 10D antigen unit and less than 20D antigen unit. In another embodiment, vaccine dose of the present invention can comprise 26-49%, 30-45%, 33-40%, the 35-37% of the standard 40D antigen unit dosage of 1 type IPV, about or accurate 1/3rd (equaling about 10.4-19.6,12-18,13.2-16,14-14.8 or 13.3D antigen unit). In another embodiment, IPV vaccine dose of the present invention can comprise 11-32 antigen unit, 12-28D antigen unit, 1 type IPV of 13-24D antigen unit or 14-20D antigen unit.
Selectively, IPV vaccine dose of the present invention can comprise 10-19.5 antigen unit, 12-19 D antigen unit, 1 type IPV of 14-18.5D antigen unit or 15-17D antigen unit; 1 type IPV of about or accurate 16D antigen unit for example.
In another embodiment, vaccine of the present invention can comprise the 2 type IPV (equaling 37.5% standard 8D antigen unit dosage) less than 4D antigen unit, about or accurate 3 D antigen units of 2-4D antigen unit (equaling the standard 8D antigen unit dosage of 25-50%).
In another embodiment, vaccine of the present invention can comprise the 2 type IPV (equal about 2.7D antigen unit) of about or accurate 1/3rd standard 8D antigen unit dosage.
In another embodiment, vaccine of the present invention can comprise 2 type IPV of 2-7D antigen unit. In another embodiment, IPV vaccine dose of the present invention can comprise 2 type IPV of 3-6D antigen unit or 4-5D antigen unit.
Selectively, IPV vaccine dose of the present invention can comprise 2 type IPV of 2-4.5D antigen unit, 2.5-4 D antigen unit or 3-3.5D antigen unit.
In another embodiment, vaccine of the present invention can comprise 8-20D antigen unit, greater than 8 but less than 20D antigen unit, 9-19D antigen unit, 10-18D antigen unit, 11-17 D antigen unit, 12-16D antigen unit, or 3 type IPV of 13-15D antigen unit; 3 type IPV of about or accurate 14D antigen unit (equaling the standard 32D antigen unit dosage of 25-62.5%, 28.125-59.375%, 31.25-46.875% or 43.75%) for example.
In another embodiment, vaccine of the present invention can comprise the 3 type IPV (equal about 10.7D antigen unit) of about or accurate 1/3rd standard 32D antigen unit dosage.
In another embodiment, IPV vaccine dose of the present invention can comprise 8-29D antigen unit, 9-26D antigen unit, 10-23D antigen unit, 11-20D antigen unit, 12-17D antigen unit, or 3 type IPV of 13-14D antigen unit.
Selectively, IPV vaccine dose of the present invention can comprise 8-19.5D antigen unit, 9-19 D antigen unit, 10-18.5D antigen unit, 11-18D antigen unit, 12-17.5D antigen unit, 13-17D antigen unit, or 14-16D antigen unit; About or accurate 15D antigen unit for example.
The DTP vaccine component
The DTP vaccine is the known vaccine that is used for prevention or treatment diphtheria, tetanus and bordetella pertussis (B.pertussis) disease.Vaccine of the present invention can comprise diphtheria, tetanus and/or pertussis component.
Diphtheria antigen is diphtheria toxoid normally.Diphtheria toxoid (DT) goods are put down in writing by lot of documents.Can use the diphtheria toxoid of any appropriate.For example, can prepare DT succeeded by chemical detoxication by culture purified toxins from diphtheria corynebacterium, but optionally reorganization or the hereditary detoxification analog by the described toxin of purification prepares (for example, CRM197, or other mutants, as US 4,709,017, US 5,843,711, US 5,601,827 and US 5,917,017 in description).In one embodiment, DT exists with the amount of about or accurate 7.5Lf of 5-50,7-30Lf or 25Lf in every 0.5mL dosage.In another embodiment, in every 0.5mL dosage DT with less than 5Lf or 1-4Lf is about or the low dosage of accurate 2Lf exists.In one embodiment, diphtheria toxoid of the present invention can be adsorbed onto aluminum salt such as on the aluminium hydroxide.In another embodiment, diphtheria toxoid of the present invention can be adsorbed onto aluminum salt such as on the aluminum phosphate.In another embodiment, diphtheria toxoid can be adsorbed onto on the mixture of aluminium hydroxide and aluminum phosphate.
Tetanus antigen of the present invention is tetanus toxoid normally.The method for preparing tetanus toxoid (TT) is well known in the art.In one embodiment,, prepare TT, but optionally reorganization or the hereditary detoxification analog by the described toxin of purification prepares (for example described in the EP 209281) succeeded by chemical detoxication by purified toxins from the culture of clostridium tetani.Can use the tetanus toxoid of any appropriate." tetanus toxoid " can comprise the immunogenic fragments (for example Fragment C-is referring to EP 478602) of full-length proteins.In one embodiment, in every 0.5mL dosage TT with 2.5-30Lf, 3-20Lf, 5-15Lf is accurate or the amount of about 10Lf exists.In one embodiment, tetanus toxoid of the present invention can be adsorbed onto aluminum salt such as on the aluminium hydroxide.In another embodiment, tetanus toxoid of the present invention can be adsorbed onto aluminum salt such as on the aluminum phosphate.In another embodiment, tetanus toxoid can be adsorbed onto on the mixture of aluminium hydroxide and aluminum phosphate.
Pertussis component of the present invention can be (Pa) (wherein using the pertussis antigen of purification) of acellular or (Pw) (whole cell pertussis that wherein uses deactivation is as pertussis component) of full cell.Pw can be by several known methods (comprising not mercurous method) deactivation.These class methods can comprise that (for example 55-65 ℃ or 56-60 ℃ is total to 5-60 minute or 10-30 minute in heating, for example 60 ℃ totally 30 minutes), (for example 0.1% at 37 ℃ for formaldehyde, 24 hours), glutaraldehyde (for example 0.05% in room temperature, 10 minutes), acetone-I (for example at room temperature handling three times) or acetone-II (for example at room temperature handle three times and carry out the 4th time at 37 ℃ and handle) deactivation is (referring to people such as for example Gupta, 1987, J.Biol.Stand.15:87; People such as Gupta, 1986, Vaccine, 4:185).The method that preparation is fit to deactivation of the present invention, whole cell pertussis bacillus (Pw) is disclosed in WO 93/24148, and it also is the suitable preparation method that produces the DT-TT-Pw-HepB vaccine.In the past, thimerosal is used to the preparation (seeing below) of the whole cell pertussis bacillus of deactivation.But in one embodiment, it is not used to the preparation process of vaccine of the present invention.
Normally used Pw dosage is 5-50IOU, 7-40IOU, 9-35IOU, 11-30IOU, the about or accurate 20IOU of 13-25IOU, 15-21IOU.
Acellular Pa vaccine also is known, can comprise following two or more antigens: DT-Pa (PT), thread hemagglutinin (FHA), pertactin (pertactin) (PRN), agglutinogen 2﹠amp; 3.In one embodiment, the Pa vaccine comprises PT, FHA and PRN.Test kit of the present invention or vaccine can comprise by known formaldehyde treated method or pass through to suddenly change the PT of (PT derivant) detoxification.Have been found that the replacement of residue in Protein S 1 subunit causes this albumen to keep immunity and the protective nature of PT, but toxicity reduces or does not have toxicity (EP322533).The detoxification mutant of describing in EP322533 claim is the example of DT detoxification mutant of the present invention.This mutant can use the dosage that is lower than 20-25 μ g.
In one embodiment, the PT amount of using in every 0.5mL dosage is 2-50 μ g, the accurate or about 25 μ g of 5-40 μ g, 10-30 μ g.In another embodiment, the PT amount of using in every 0.5mL dosage is 2.5 or 8 μ g.
In one embodiment, the FHA amount of using in every 0.5mL dosage is 2-50 μ g, the accurate or about 25 μ g of 5-40 μ g, 10-30 μ g.In another embodiment, the FHA amount of using in every 0.5mL dosage is accurate or about 2.5 or 8 μ g.
In one embodiment, the PRN amount of using in every 0.5mL dosage is 0.5-20 μ g, the accurate or about 8 μ g of 0.8-15 μ g, 2-10 μ g.In another embodiment, the PRN amount of using in every 0.5mL dosage is accurate or about 0.8 or 2.5 μ g.
In one embodiment, pertussis component of the present invention can be adsorbed onto aluminum salt such as on the aluminium hydroxide.In another embodiment, pertussis component of the present invention can be adsorbed onto aluminum salt such as on the aluminum phosphate.In another embodiment, the pertussis component can be adsorbed onto on the mixture of aluminium hydroxide and aluminum phosphate.For example in one embodiment, PRN is adsorbed onto on the aluminium hydroxide at least, and PT/FHA is adsorbed onto on aluminium hydroxide, aluminum phosphate or the two the mixture.
Other antigens
Bacterin preparation of the present invention, the optional DTP (DTPw or DTPa) that also comprises can also comprise being selected from one or more following antigens: hepatitis B surface antigen, b type hemophilus influenza antigen, A type hitchens and Hansen antigen, C type hitchens and Hansen antigen, W-135 type hitchens and Hansen antigen, Y type hitchens and Hansen antigen, Type B meningococcus bleb or purifying antigen, hav antigen, salmonella typhi antigen and RTS, S.Usually can use the capsular saccharides or the LOS antigen of these pathogen.Antigen exists with the concentration of every kind 1 μ g/mL at least usually, for example 1-20 μ g/mL, 2-15 μ g/mL, 2.5-10 μ g/mL, 3-8 μ g/mL or 4-6 μ g/mL.Usually, any antigenic concentration will be enough to cause anti-this antigenic immunne response.Preferred single antigenic protection effect is not removed because of their mixing, but in fact immunogenicity (for example ELISA titre) may be weakened.
In one embodiment of the invention, other antigens can be adsorbed onto aluminum salt such as on the aluminium hydroxide.In another embodiment, other antigens of the present invention can be adsorbed onto aluminum salt such as on the aluminum phosphate.In another embodiment, other antigens can be adsorbed onto on the mixture of aluminium hydroxide and aluminum phosphate, maybe can be non-adsorbable.
When using capsular saccharides or LOS antigen, it can be conjugated to the carrier protein that comprises the auxiliary epi-position of T, so that enhance immunity originality.The present invention also can comprise free " carrier protein ".
As the replacement of in the present composition, using proteantigen, can use the described antigenic nucleic acid of coding.Therefore the protein component of the present composition this proteic nucleic acid (for example DNA, it can adopt the form of plasmid) that can be encoded replaces.Similarly, compositions of the present invention can comprise the albumen of simulation carbohydrate antigen such as mimotope or anti-id AB.These can replace independent saccharic composition, or they are replenished.
Hepatitis B antigen
Hepatitis B surface antigen (HBsAg) goods are put down in writing by lot of documents.Referring to for example, people such as Hartford, 1983, Develop.Biol.Standard 54:125, people such as Gregg, 1987, Biotechnology 5:479, EP0226846, EP0299108.It can be prepared as follows.A kind of method relates to from the antigen of the blood plasma purification particulate form of chronic viral hepatitis B carrier, because a large amount of HBsAg is synthetic in liver, and is discharged in the blood flow between the HBV infection period.Another kind method relates to by recombinant DNA method expresses this albumen.Can prepare HBsAg by in saccharomyces cerevisiae (Saccharomyces cerevisiae), Pichia sp., insect cell (for example Hi5) or mammalian cell, expressing.HBsAg can be inserted plasmid, and control its expression in plasmid by promoter such as " GAPDH " promoter (from glyceraldehyde-3-phosphate glue hydrogenase gene).Described yeast can be cultivated in synthetic medium.Then by comprising method Purification of HBsAg such as steps such as precipitation, ion-exchange chromatography and ultrafiltration.Behind the purification, HBsAg can be dialysed (for example using cysteine).Can use the HBsAg of particulate form.
Statement " hepatitis B surface antigen " or " HBsAg " comprises that any HBsAg antigen or its show antigenic fragment of HBV surface antigen as used herein.Should be appreciated that and remove HBsAg S antigen 22 six amino acid sequence (referring to people such as Tiollais, 1985, Nature 317:489 and wherein list of references) outside, if desired, HBsAg described herein can comprise all or part of of pre-S sequence that above-mentioned list of references and EP0278940 describe.Especially, HBsAg can comprise a kind of polypeptide that comprises aminoacid sequence, and with respect to the open reading frame of the hepatitis B virus of ad serotype, it is that (this polypeptide is known as L for the proteic residue of L of HBsAg that described aminoacid sequence comprises residue 133-145 back *Referring to EP0414374).HBsAg in the scope of the invention can also comprise preS1-preS2-S polypeptide or its analog that EP0198474 (Endotronics) describes, those that describe such as EP0304578 (McCormick and Jones).HBsAg described herein can also relate to mutant, for example WO 91/14703 or EP0511855A1 " escape mutant (the escape mutant) " that describe, and especially 145 aminoacid replacement is to become arginic HBsAg from glycine.
HBsAg can adopt particle form.It maybe can be that composite particles is (such as L that described granule can comprise such as independent S albumen *, S), L wherein *As mentioned above, S represents the S albumen of HBsAg.Described granule advantageously adopts the form of expressing in yeast.
In one embodiment, HBsAg is EngerixB TMThe antigen that uses in (GlaxoSmithKlineBiologicals S.A.), it is further described in WO93/24148.
In one embodiment, HBsAg exists with 5-20 μ g, 8-15 μ g amount about or accurate 10 μ g in every 5mL dosage.
Hepatitis B surface antigen can be adsorbed onto on the aluminum phosphate, this can with finish (being described in WO93/24148) before other components are mixed.The hepatitis B component should be substantially free of thimerosal (preparation method of the HBsAg of no thimerosal had before had been disclosed in EP1307473).
B type hemophilus influenza antigen
WO97/00697 has described and has comprised from the antigenic vaccine of Type B hemophilus influenza.Vaccine of the present invention can use the Type B hemophilus influenza antigen of any appropriate.Described antigen can be the capsular saccharides of puting together with carrier protein (Hib) from the Type B hemophilus influenza (PRP).Described sugar is the polymer of ribose, ribitol and phosphate ester.What Hib antigen can be chosen wantonly is adsorbed onto on the aluminum phosphate as described in WO97/00697, or is non-adsorbable as described in WO02/00249, or does not also experience specific adsorption step.
The antigen that " is not adsorbed onto on the aluminium adjuvant salt " is meant that the clear and definite or single-minded adsorption step of antigen on fresh aluminium adjuvant salt for example do not participate in the step of compositions formulated herein.
Hib can be conjugated to any carrier, and described carrier provides at least one T to assist epi-position (example is described hereinafter), and it can be tetanus toxoid, diphtheria toxoid, CRM-197 (diphtheria toxin mutation) or protein D.
Hib can be by lyophilizing, and can face with preceding reconstruction (for example using diluent, optional other antigenic components that comprise vaccine of the present invention).
In one embodiment, Hib amounts about with 5-20 μ g, 8-15 μ g or accurate 10 μ g sugar exist in every 5mL dosage.
In another embodiment, Hib exists with WO 02/00249 described low dosage (for example about or accurate 2.5 μ g sugar of 1-6 μ g, 2-4 μ g).
Meningococcus A, C, W or Y type antigen
Vaccine of the present invention can also comprise the capsular saccharides of antibacterial, it is selected from: A type meningococcus (MenA, optional puts together with carrier protein), C type meningococcus (MenC, optional puts together with carrier protein), W-135 type meningococcus (MenW, optional puts together with carrier protein) and Y type meningococcus (MenY, optional puts together with carrier protein).
Vaccine of the present invention can comprise from meningococcus one or more antigens of homophyletic not, as the following detailed description, its can use separately or with 2,3 or any combination of 4 kind of component use:
MenA, MenC, MenW, MenY, or MenA+MenC, MenA+MenW, MenA+MenY, MenC+MenW, MenC+MenY, MenW+MenY or MenA+MenC+MenW, MenA+MenC+MenY, MenA+MenW+MenY, MenC+MenW+MenY or MenA+MenC+MenW+MenY.
In one embodiment, meningococcus component of the present invention can be adsorbed onto aluminum salt such as on the aluminium hydroxide.In another embodiment, meningococcus component of the present invention can be adsorbed onto aluminum salt such as on the aluminum phosphate.In another embodiment, the meningococcus component can be adsorbed onto on the mixture of aluminium hydroxide and aluminum phosphate.In one embodiment, the meningococcus component can not be adsorbed onto adjuvant such as on the aluminium adjuvant salt.
Type B meningococcus type bleb or antigen
Vaccine of the present invention can also comprise the MenB component, such as outer membrane vesicles or bleb (describing in WO01/09350, WO03/105890, WO04/014417 or WO04/014418) or MenB capsular saccharides (or derivatives thereof) antigen of puting together (for example referring to WO 96/40239) or L2 or L3 or L2 and the meningococcal LOS of L3 (according to WO2004/014417) free or that put together.In one embodiment, MenB component of the present invention can be adsorbed onto aluminum salt such as on the aluminium hydroxide.In another embodiment, MenB component of the present invention can be adsorbed onto aluminum salt such as on the aluminum phosphate.In another embodiment, the MenB component can be adsorbed onto on the mixture of aluminium hydroxide and aluminum phosphate.In one embodiment, the MenB component can not be adsorbed onto adjuvant such as on the aluminium adjuvant salt.
Salmonella typhi antigen
Vaccine of the present invention can also comprise the Vi sugar from salmonella typhi, and it can be the product of registration
Figure A200780041465D0022134930QIETU
, be described in EP1107787, or its conjugate (for example with carrier protein described herein).Can put together step according to the description of WO 2007/000343.In one embodiment, Vi sugar of the present invention can be adsorbed onto aluminum salt such as on the aluminium hydroxide.In another embodiment, Vi sugar of the present invention can be adsorbed onto aluminum salt such as on the aluminum phosphate.In another embodiment, Vi sugar can be adsorbed onto on the mixture of aluminium hydroxide and aluminum phosphate.In one embodiment, Vi sugar can not be adsorbed onto adjuvant such as on the aluminium adjuvant salt.
Hav antigen
The component that can prevent hepatitis A can be the attenuated hepatitis A vaccine of deactivation, such as being called Havrix TMProduct (registered trade mark of GlaxoSmithKline Biologicals S.A.), its be derived from the HM-175 strain of hepatitis A virus (HAV) (HAV) the deactivation attenuated vaccine (referring to " InactivatedCandidate Vaccines for Hepatitis A (the deactivation candidate vaccine of hepatitis A) ", people such as F.E.Andre, 1980, Prog.Med.Virol.37:72 and product Feature article " Havrix " are published in 1991 by SmithKline Beecham Biologicals).People such as Flehmig (1990, Prog.Med Virol.37:56) have summarized clinical condition, virusology, immunology and the epidemiology of hepatitis A, and have described the method for the vaccine of anti-this class common virus infection of exploitation.Be meant can be at any antigen of human body moderate stimulation at the neutralizing antibody of HAV in statement " HAV antigen " as used herein.In one embodiment, HAV antigen comprises the attenuated virus granule of deactivation, or in another embodiment, HAV antigen may be HAV capsid or HAV virus protein, and it can obtain by the DNA recombinant technique easily.In one embodiment, hepatitis A component of the present invention can be adsorbed onto aluminum salt such as on the aluminium hydroxide.In another embodiment, hepatitis A component of the present invention can be adsorbed onto aluminum salt such as on the aluminum phosphate.In another embodiment, the hepatitis A component can be adsorbed onto on the mixture of aluminium hydroxide and aluminum phosphate.
Malaria antigen
Vaccine of the present invention can also comprise malaria antigen.Malaria antigen can be RTS, S (hybrid protein of CS and HBsAg-be described in US 6,306,625 and EP 0614465).In one embodiment, RTS, S can be used for vaccine of the present invention to substitute HBsAg.Other malaria antigens also can be used for vaccine of the present invention, comprise CS albumen, RTS, TRAP, the 16kD albumen of B 2992, AMA-1, MSP1, optional comprise CpG (WO2006/029887, WO98/05355, WO01/00231).
In one embodiment, malaria antigen of the present invention can be adsorbed onto aluminum salt such as on the aluminium hydroxide.In another embodiment, malaria antigen of the present invention can be adsorbed onto aluminum salt such as on the aluminum phosphate.In another embodiment, malaria antigen can be adsorbed onto on the mixture of aluminium hydroxide and aluminum phosphate.In one embodiment, malaria antigen usefulness O/w emulsion and/or lipoid A derivant (such as MPL) and/or sterol (such as cholesterol) and/or tocopherol (such as alpha-tocopherol) are as adjuvant.In another embodiment, malaria antigen can not be adsorbed onto adjuvant such as on the aluminium adjuvant salt.
Conjugate
Bacterial capsule glycoconjugate of the present invention can comprise any carrier peptides, polypeptide or albumen that comprises the auxiliary epi-position of at least one T.The carrier protein that uses can be selected from: tetanus toxoid, diphtheria toxoid, CRM197, recombined diphtheria toxin is (as US 4,709,017, arbitrary described among WO 93/25210, WO 95/33481 or the WO 00/48638), pneumolysin (optional chemical detoxication from streptococcus pneumoniae (S.pneumoniae), or detoxification mutant) (referring to for example WO 2004/081515 and the list of references quoted thereof), from meningococcal OMPC (EP0372501) with from the protein D (PD) (EP 594610) of hemophilus influenza.Other carriers can comprise synthetic peptide, and (EP 0378881; EP 0427347), (WO 93/17712 for heat shock protein; WO 94/03208), (WO 98/58668 for pertussis albumen; EP 0471177), cytokine (WO91/01146), lymphokine (WO 91/01146), hormone (WO 91/01146), somatomedin (WO91/01146), comprise from the originate artificial protein (people such as Falugi of antigenic various human CD4+ t cell epitope of various pathogen, 2001, Eur.J.Immunol.31:3816), streptococcus pneumoniae surface protein PspA (WO 02/091998), ferrum picked-up albumen (WO 01/72337), the toxin A of clostridium difficile (C.difficile) or B (WO 00/61761), streptococcus pneumoniae PhtD (WO 00/37105), streptococcus pneumoniae PhtDE (WO 01/98334 ﹠amp for example; WO 03/054007), PhtX, or the like.
All sugar can be on same vehicle, and especially from all sugar of a specific organism, for example MenA, MenC, MenW and MenY sugar can all be conjugated on TT, DT or the CRM-197.But, because known carrier inhibitory action, if may be favourable with surpassing that a kind of carrier puts together with the carbohydrate antigen (" n " individual antigen) that comprises in every kind of compositions of the present invention.Therefore (n-1) of described sugar is individual can carry (independent) on a kind of bearer type, 1 on different carriers, or (n-2) individual on a kind of bearer type, 2 on different carriers, or the like.For example, in the vaccine that comprises 4 antibacterial glycoconjugates, 1,2 or all 4 can put together with different carriers.But protein D can be used for various (2,3, the 4 or more a plurality of) sugar in the compositions and does not have significant carrier inhibitory action.Hib can TT, DT or the form of CRM197 conjugate exist, MenA, MenC, MenY and MenW can be TT, DT, CRM197 or PD conjugate.Vi can TT, DT or the form of CRM197 conjugate exist.Protein D is a kind of useful carrier, because it provides a kind of other antigens that can the flu-prevention haemophilus.In one embodiment, all sugar are all puted together with identical carrier protein.
For example Vi and carrier protein can be puted together by the method for utilizing carbodiimides (for example EDAC) condensation chemistry (considering that Vi repeats subunit and comprises carboxyl).This can realize by following reaction: (i) the single carbodiimides reaction between the COOH of Vi and the proteic NH2 or (ii) two carbodiimides reaction, it occurs between the NH2 of the NH2 of the COOH of Vi and linkers and proteic COOH and homogeneity bifunctional linker molecule, or between the COOH of the NH2 of the COOH of Vi and heterogeneous bifunctional linker molecule and proteic NH2 and heterogeneous bifunctional linker molecule.
Put together the connection that can be used for free carrier protein.In one embodiment, when specified carrier protein in the present composition with free and put together form when existing, unconjugated form is no more than 5% of carrier protein total amount in the whole compositions, or unconjugated in another embodiment form is by weight less than 2%.
Can use any known method (for example, Likhite, United States Patent (USP) 4,372,945 and people such as Armor, United States Patent (USP) 4,474,757), utilize any suitable joint where necessary, sugar is connected with carrier protein.
Before puting together, sugar is activated or functionalization usually.Activation can relate to, for example, and cyaniding (cyanylating) reagent such as CDAP (1-cyano group-dimethyl aminopyridine tetrafluoroborate) (WO 95/08348 ﹠amp; WO 96/29094).Cyaniding (cyanylating) reaction can be carried out under gentle relatively condition, and this can be avoided the hydrolysis of the responsive sugar of alkalescence.This synthetic permission directly is conjugated to carrier protein.Other suitable technique are used carbodiimides, hydrazides, active ester, norbornane, Nitrodracylic acid, N-hydroxy-succinamide ester, S-NHS, EDC or TSTU.
Can utilize any known step, such as US 4,882,317 and the step described of US 4,695,624, finish connection by the joint group.One class connects the reductive amination relate to sugar, the amino end with adipic acid joint group of obtain is puted together (EP 0477508, people such as Porro, 1985, Mol.Immunol.22:907, EP 0208375), then another end of albumen and adipic acid joint group is puted together.Other joints comprise B-propionamido-(WO 00/10599), and nitrobenzophenone-ethamine (people such as Gever, 1979, Med.Microbiol.Immunol.165:171), carboxylic acid halides salt (US 4,057,685), glycosidic bond (US 4,673, and 574; US 4,761, and 283; US 4,808,700), 6-aminocaprolc acid (US 4,459,286), ADH (US 4,965,338), C4 be to C12 group (US4,663,160), or the like.As the alternative method of using joint, can use direct connection.Directly be connected the oxidation that can comprise sugar with proteic, succeeded by described proteic reductive amination, such as US 4,761,283 and US 4,356,170 in description or directly CDAP reaction.
After puting together, can separated free and the sugar of puting together.There are a lot of isolating methods of this class that are fit to, comprise hydrophobic chromatography, tangential ultrafiltration, diafiltration, or the like (also can be referring to people such as Lei, 2000, DevBiol. (Basel) .103:259; WO 00/38711; US 6,146, and 902).In one embodiment, if vaccine comprises free and puts together the specified sugar of two kinds of forms, do not put together form is no more than this sugar total amount by weight in whole compositions 20% (for example≤15% ,≤10% ,≤5% ,≤2% ,≤1%).
Can determine by the technical staff for the host provides the sugar amount (effective dose) of protection.An embodiment, every dosage will comprise the sugar of 0.1-100 μ g, every in another embodiment dosage will comprise 0.1-50 μ g, and every dosage will comprise 0.1-10 μ g in further embodiment, and still every in another embodiment dosage will comprise 1-5 μ g.
Adjuvant
Vaccine of the present invention can comprise that pharmaceutically acceptable excipient is such as suitable adjuvant.Suitable adjuvant comprises aluminum salt such as aluminium hydroxide or aluminum phosphate, but also can be calcium salt; iron salt or zinc salt maybe can be the insoluble suspensions of acidylate tyrosine (MPL); or acidylate sugar, maybe can be the sugar of cation or anionic derivative, polyphosphazene; biodegradable microsphere, monophosphoryl lipid A (MPL), lipoid A derivant (for example having the toxicity that weakens); 3-O-deacylated tRNA MPL; quil A, saponin, QS21; tocopherol (EP 0382271); incomplete Freund (Difco Laboratories, Detroit, MI); Merck Adjuvant 65 (Merck and Company; Inc., Rahway, NJ); AS-2 (Smith-Kline Beecham; Philadelphia, PA), the CpG oligonucleotide; bioadhesive polymer and mucomembranous adhesion agent; microgranule, liposome, polyoxyethylene ether preparation; the polyoxyethylene ester formulation, muramyl peptide or imidazoquinolie (for example imiquimod and homologue thereof).The human immunity regulator that is suitable as adjuvant in the present invention comprises cytokine such as interleukin (IL-1 for example, IL-2, IL-4, IL-5, IL-6, IL-7, IL-12, or the like), M-CSF (M-CSF), tumor necrosis factor (TNF), granulocyte macrophage colony stimulating factor (GM-CSF) also can be used as adjuvant and use.
In one embodiment of the invention, the adjunvant composition of described preparation is mainly induced the immunne response of TH1 type.High-caliber TH1 cytokines (for example IFN-γ, TNF α, IL-2 and IL-12) tends to promote to induce the cell-mediated immune responses at institute's administration of antigens.Replying mainly is in the embodiment of TH1 type, and the level of TH1 cytokines will be increased to the degree that is higher than TH2 cytokines level.Utilize standard analysis can estimate the level of these cytokines easily.For the summary of cytokine family, can be referring to Mosmann and Coffman, 1989, Ann.Rev.Immunol.7:145.
Therefore; the main suitable adjuvant system that promotes TH1 to reply comprises; the derivant of lipoid A (for example having the toxicity that weakens); monophosphoryl lipid A (MPL) or derivatives thereof; especially 3-deoxidation-acidylate monophosphoryl lipid A (3D-MPL); and the combination of monophosphoryl lipid A, optional 3-deoxidation acidylate monophosphoryl lipid A and aluminum salt.The enhancing system relates to the combination of monophosphoryl lipid A and saponin derivative, and the especially combination of WO 94/00153 disclosed QS21 and 3D-MPL, or WO 96/33739 is disclosed to cause reactive lower compositions, wherein QS21 cholesterol quencher.The especially effectively adjuvant that comprises the QS21, the 3D-MPL that are dissolved in O/w emulsion and tocopherol is described in WO 95/17210.Described vaccine can also comprise saponin, and it can be QS21.Described preparation can also comprise O/w emulsion and tocopherol (WO 95/17210).Comprise the non-methylated CpG (WO 96/02555) of oligonucleotide or the preferred inducer that TH1 replys, and be applicable to the present invention.
Vaccine of the present invention can also comprise the combination of above-mentioned one or more adjuvants of the present invention.
Any adjuvant of the present invention can be adsorbed onto IPV component of the present invention or with its combination.
When relating to aluminium hydroxide or aluminum phosphate, the reference of all aluminium hydroxide and/or aluminum phosphate is all according to Hem and White (Pharm Biotechnol.1995; Description 6:249-276).
In one embodiment, aluminum phosphate also can be known as Adju-Phos.In another embodiment, aluminum phosphate is to have negative charge at 7.4 o'clock at pH.Usually, the isoelectric point, IP of aluminum phosphate (pI) is that 5-7 or 6-7 are about or accurate 5.In another embodiment, phosphoric acid in the aluminum phosphate: the molar ratio of aluminum is 0.3-0.9 or 0.3-0.6 or 0.8-0.9.
In one embodiment, aluminium hydroxide is to have positive charge at 7.4 o'clock at pH.Usually, the pI of aluminium hydroxide is 8-11,9-11,10-11 is about or accurate 11.
Usually, the total amount of aluminum is 200-1000 μ g in every 0.5mL dosage, 300-900 μ g, 400-800 μ g, the about or accurate 630 μ g Al of 500-700 μ g 3+This is applicable to all aluminium hydroxide or all aluminum phosphate.Selectively, Al 3+Content may be from the aluminum phosphate of the aluminium hydroxide of following ratio and the mixture of aluminum phosphate: 1:8-8:1,1:4-4:1,3:8-8:3,1:2-2:1 or 1:1: aluminium hydroxide.In one embodiment, the aluminum phosphate that uses: the aluminium hydroxide ratio is 12:1-4:1,11:1-5:1,10:1-6:1,9:1-7:1 or 8:1.
Although most of aluminum provides with the antigenic form of preadsorption before mixing the formation combined vaccine, some aluminum can add with free form during preparation combined vaccine of the present invention, for example before pH regulator step described herein.Usually, the content of free aluminum can be 0-300 μ g in every 0.5mL dosage, 50-250 μ g, 75-200 μ g, the Al3 of the about or accurate 115 μ g of 100-150 μ g +Free Al 3+Can all be Al (OH) 3Or all be AlPO 4, or the Al of following ratio (OH) 3And AlPO 4Mixture (w:w Al 3+: Al 3+): 1:1-1:6,1:1.1-1:5,1:1.2-1:4,1:1.3-1:3,1:1.4-1:2, for example 23/92 or 69/46 or 6:1-1:1,5:1-1.1:1,4:1-1.2:1,3:1-1.3:1,2:1-1.4:1, for example 46/69 or 92/23.
Optionally some component of vaccine of the present invention can not be specially to be adsorbed onto adjuvant especially on the aluminum salt.
IPV can not adsorb or be adsorbed onto Al (OH) 3Or Al (OH) 3And AlPO 4Mixture on.DT can be adsorbed onto Al (OH) 3Or AlPO 4On, TT can be adsorbed onto Al (OH) 3Or AlPO 4On, Pw can be adsorbed onto AlPO 4Upward or with it mix, PRN can be adsorbed onto Al (OH) 3On, FHA can be adsorbed onto Al (OH) 3On, PT can be adsorbed onto Al (OH) 3On, HB can be adsorbed onto AlPO 4On, Hib can be adsorbed onto AlPO 4Go up or do not adsorb, Men ACWY can be adsorbed onto Al (OH) 3Or AlPO 4Go up or do not adsorb, the MenB component can be adsorbed onto Al (OH) 3Or AlPO 4Go up or do not adsorb, Vi can be adsorbed onto Al (OH) 3Or AlPO 4Go up or do not adsorb, HepA can be adsorbed onto Al (OH) 3Or AlPO 4On.
The antigen of preadsorption to the aluminum salt can be before mixing preadsorption separately.In another embodiment, with can be before other adjuvants mix with antigenic mixture preadsorption.In one embodiment, IPV can adsorb respectively or as the absorption of the mixture of 1,2 and 3 type IPV, or adsorbs when mixing with the D of absorption and T component.
The implication of " antigen of absorption " is for example to represent greater than 20%, 30%, 40%, 50%, 60%, 70%, and 80% or 90% absorption.
Term " aluminum phosphate " and " aluminium hydroxide " comprise the aluminium hydroxide or the aluminum phosphate of the form of ownership that is suitable as vaccine adjuvant as used herein.For example, aluminum phosphate can be the precipitate (unbodied, hemicrystalline or crystalline) of insoluble aluminum phosphate, and it is optional but be not that unique passing through mixes aluminum soluble salt and phosphate prepares." aluminium hydroxide " can be the precipitate (unbodied, hemicrystalline or crystalline) of insoluble aluminium hydroxide, and it is optional but be not in unique the passing through and aluminum salt solution prepares.Especially suitable is the various forms of aluminium hydroxide and the Fosfalugel (Yamanouchi) that can obtain from the commercialization source, Alhydrogel (the aluminium hydroxide that provides such as Brenntag Biosector (Denmark), 3% water-soluble suspension) and Adjuphos (aluminum phosphate is dissolved in brinish 2% suspension).
The non-immune component of vaccine of the present invention
Except antigen mentioned above and adjuvant component, vaccine of the present invention generally includes one or more " pharmaceutically acceptable carrier or excipient ", and it comprises self does not induce any excipient that the individual deleterious antibody of accepting described compositions is generated.Suitable excipient normally big, metabolism slowly macromole such as albumen, sugar, polylactic acid, polyglycolic acid, polyamino acid, amino acid copolymer, sucrose (people such as Paoletti, 2001, Vaccine, 19:2118), trehalose (WO00/56365), lactose and lipoid aggregation (such as oil droplet or liposome).This class carrier is known for those of ordinary skills.Described vaccine can also comprise diluent, such as water, and saline, glycerol, or the like.In addition, can also there be adjuvant, such as wetting agent or emulsifying agent, the pH buffer agent, or the like.Aseptic normal saline pyrogen-free, phosphate-buffered is a kind of typical carriers.Can be about thoroughly discussing of pharmaceutically acceptable excipient referring to list of references Gennaro, 2000, Remington:The Science and Practice of Pharmacy, 20 ThVersion, ISBN:0683306472.
Compositions of the present invention can be freeze dried or adopt aqueous form, ie in solution or suspension.The liquid preparation of this class allows directly to use from the packaged form of compositions, need not to rebuild in aqueous medium, therefore is applicable to injection.Compositions may reside in the bottle, or they may reside in the syringe of pre-filling.Described syringe can provide syringe needle or syringe needle is not provided.Injection will comprise the compositions of single dose, and bottle can comprise single dose or multiple dose (for example 2 dosage).In one embodiment, described dosage is used for the people.In another embodiment, described dosage is used for the adult, and the youth begins to learn the child who walks, and baby or less than 1 years old people can use by injection.
Aqueous vaccine of the present invention also is suitable for rebuilding other vaccines from lyophilized form.When vaccine is used to face with preceding reconstruction, the invention provides a kind of test kit, it can comprise two bottles, maybe can comprise syringe and bottle of pre-filling, has the syringe contents that is used for rebuilding the bottle inclusions before injection.
Vaccine of the present invention can be packaged into unit dosage form or multiple dose form (for example 2 dosage).For the multiple dose form, bottle is better than pre-filled syringe.Effectively dose volume can be determined as usual, and the typical human dosage that singly is used to the compositions of injecting is the 0.5mL volume.
In one embodiment, the pH of vaccine of the present invention is 6.0-8.0, and in another embodiment, the pH of vaccine of the present invention is 6.3-6.9, for example 6.6 ± 0.2.Vaccine can be cushioned at this pH.Can keep stable p H by using buffer.If compositions comprises aluminium hydroxide salt, can use histidine buffering liquid (WO03/009869).Compositions should be aseptic and/or pyrogen-free.
Compositions of the present invention should be isoosmotic for the mankind.
Vaccine of the present invention can comprise antimicrobial, especially when being packaged as the multiple dose form.Should avoid thimerosal because this loss that causes the IPV component to be renderd a service.Also can use other antimicrobials, such as 2-phenoxyethanol or p-hydroxybenzoic acid (methyl, ethyl, propyl group p-hydroxybenzoic acid).Any antiseptic preferably exists with low-level.Antiseptic can external source add, and/or can be initial antigenic component, the described compositions of its mixed formation (for example the antiseptic as pertussis antigen exists).
In one embodiment, vaccine of the present invention is not contain thimerosal or be substantially free of thimerosal." do not contain thimerosal " or " being substantially free of thimerosal " expression does not exist in the final preparation and is enough to the thimerosal that the effectiveness to the IPV component has a negative impact.For example, if in Pw or hepatitis B surface antigen purge process, use thimerosal, its should with removed basically before IPV mixes.Sodium Mercurothiolate content in the whole vaccine should be lower than 0.025 μ g/ μ g albumen, 0.02 μ g/ μ g albumen, 0.01 μ g/ μ g albumen or 0.001 μ g/ μ g albumen, for example 0 μ g/ μ g albumen.In one embodiment, neither add thimerosal, also in the purification of any component, do not use thimerosal.Referring to for example EP1307473, referring to above, wherein deactivation is to finish under the situation that no thimerosal exists for the Pw step for hepatitis B.
Vaccine of the present invention can comprise for example Tween (polysorbate) of detergent, such as Tween 80.Detergent normally exists with low-level, for example＜0.01%.
Vaccine of the present invention can comprise the sodium salt (for example sodium chloride) of prescribed tension.Described compositions can comprise sodium chloride.In one embodiment, the concentration range of sodium chloride is 0.1 to 100mg/mL (1-50mg/mL for example, 2-20mg/mL in the present composition, 5-15mg/mL), in another embodiment, the concentration of sodium chloride is 10 ± 2mg/mL NaCl, for example about 9mg/mL.
Vaccine of the present invention generally includes buffer.Phosphate or histidine buffering liquid are typical case's representatives.
Vaccine of the present invention can comprise free phosphate ion in the solution (for example by use phosphate buffer), does not antigenicly adsorb so that help.In one embodiment, the concentration of free phosphate ion is 0.1-10.0mM in the present composition, or in another embodiment, its concentration is 1-5mM, or its concentration is 2.5mM in further embodiment.
The character of vaccine of the present invention
In one embodiment, vaccine of the present invention is formulated as in the following manner to the vaccine of using in the host, and the single item grouping of compositions is configured to and makes the immunogenicity of single item grouping do not damaged by other single item grouping of said composition basically in this mode." be not compromised basically " when being illustrated in immunity, when the antibody titer of anti-each component of acquisition is used separately greater than this antigen 60%, 70%, 80% or 90% of the titre that obtains, or 95-100%.Therefore, in preferred embodiments, compare, do not have (significantly) adverse effect (according to the protectiveness effect) of other components in combined vaccine with using separately of other components in the combined vaccine.
Bacterin preparation
In one embodiment, vaccine of the present invention is formulated as to the vaccine of using in the host, like this they provide the antibody titer that is higher than the serum protective standard for each antigen component in the human experimenter that can accept ratio.This is an important tests estimating vaccine effect in whole colony.Antigen with associated antibodies titre (surpass this titre and just think that the host is anti-this antigen by seroconversion) is known, and described titre is open by mechanism (such as WHO).In one embodiment, surpassing 80% in the statistically evident sample of experimenter is seroconversion, in another embodiment, surpassing 90% in the statistically evident sample of experimenter is seroconversion, in further embodiment, surpassing 93% in the statistically evident sample of experimenter is seroconversion, and still in another embodiment, 96-100% is seroconversion in the statistically evident sample of experimenter.
Antigenic amount is through selecting, can protecting the amount of replying and do not have remarkable adverse side effect by induction of immunity in typical vaccine in every kind of vaccine dose.This amount will depend on that the specific immune of use is former and different.Usually each dosage of expection will comprise whole immunogens of 1-1000 μ g, or 1-100 μ g, or 1-40 μ g, or 1-5 μ g.The only amount of specific vaccine can be by determining, and described research relates to antibody titer and other reactions of observing the experimenter.The primary vaccination process can comprise the vaccine of 2-3 dosage, 1 to 2 months at interval, for example according to WHO for the recommendation of DTP immunity (promptly life 1 year).Booster dose can be carried out in 1 year of life and/or time afterwards.
Render a service by Polio in the rat of serum neutralization test mensuration
For purposes of the present invention, being used for the analysis that IPV quantitative assessment the present invention comprises the vaccine potency of IPV vaccine should utilize single dose vaccine to carry out, and should implement the ratio of reference vaccine GMT by determination test vaccine geometric mean titer (GMT), it is registered as relative response (RR) or relative effectivenes (RP) at last.With reference to GMT can be the GMT that any IPV vaccine by the 1-2-3 type IPV that comprises 40-8-32D antigen unit respectively obtains, and also can be by known vaccine
Figure A200780041465D00311
The GMT that obtains.Usually, the following RP that carries out tests:
Determine the effectiveness of 1,2 and 3 type polioviruses in the rat by serum neutralization test:
● give the group intramuscular inoculation test specimen of 10 healthy rats (strain of Sprague-Dawley (OFA) or any preclear) or the dilution (1/1.25 of reference material; 1/3.125; 1/7.81) (being dissolved in the phosphoric acid brine buffer solution).If necessary, by inoculating undiluted vaccine and aforementioned 3 kinds of dilutions expand to 4 kinds of dilutions with dilution range.The rat of 10 inoculation diluent is used as negative control.Weekly observation rat is to detect any abnormal response.Deep anaesthesia is carried out to every animal in inoculation back 20 to 22 days, and blood sampling is also collected serum to analyze by serum neutralization test.
● in order to carry out serum neutralization test, by 30 minutes inactivated serums of incubation in 56 ℃ water-bath.Utilize suitable diluent media on microplate, to prepare 3 kinds of serial dilution things of serum, every kind of a kind of poliomyelitis type of correspondence.With plate 4 ℃ of preservations.
For 3 kinds of poliovirus types, with the virus (30-300CCID of scheduled volume 50) add in the serum dilution.3 kinds of viral suspensions dilute according to their titres separately.Final dilution is called as " work dilution ".Add each work dilution to corresponding microplate.Then with plate sealing, 37 ℃ ± 1 ℃ incubation 16 hours.Add the Hep-2 cell then, with microplate 37 ℃ ± 1 ℃ incubation 7 days.After Coomassie blue stain, utilize the cellular pathogenic effect (CPE) of inverted microscope record virus.The existence of poliomyelitis antibody suppresses the growth of virus and the appearance of corresponding CPE.The final dilution inverse of poliomyelitis virus titer (1,2 and 3 type) any CPE that is equal to nothing.In every group, record has the animal of neutralizing antibody, and measures in each blood serum sample the antibody titer at dissimilar polioviruses.NAT is represented with the log2 of the inverse of the high dilution (suppressing the cytopathic effect of poliovirus to the Hep-2 cell fully) of blood serum sample.
● also measure the geometric mean titer (GMT) of each dilution factor and every kind of Virus Type in every group of rat.
The packing of vaccine of the present invention
Vaccine of the present invention can be packaged in various types of containers, bottle for example, and syringe, or the like.Multidose vial will comprise reclosable plastics spout usually, can insert the vaccine of drawing dose by this bottleneck aseptic syringe needle, can seal this bottleneck once more after syringe needle is moved out of.
Described vaccine can be in different containers (for example 2 or 3) provides.Inclusions in the described container can be mixed before using by single injection to the host temporarily, maybe it can be used in different sites simultaneously.If test kit is to use (in two or more containers) simultaneously, the dosage of then described vaccine or each vaccine is 0.5mL normally.
In an embodiment of this respect of the present invention; the test kit that comprises two kinds of polyvalent vaccines is provided; described vaccine provides the protection of resist the disease in the host; described disease is by poliovirus; bordetella pertussis; clostridium tetani, one or more in diphtheria corynebacterium and optional hepatitis B, Type B hemophilus influenza, A type meningococcus, C type meningococcus, W type meningococcus, Y type meningococcus, Type B meningococcus, salmonella typhi, hepatitis A or the malaria cause.
Described test kit comprises first container, and it comprises:
(1) (a) poliovirus of deactivation of the present invention (IPV),
(b) diphtheria toxoid (DT or D) (referring to above),
(c) tetanus toxoid (TT or T) (referring to above),
(d) deactivation complete-cell pertussis bacillus (Pw) or two or more acellular pertussis components (Pa) (referring to above),
(e) Ren Xuan hepatitis B surface antigen (HepB or HB) (referring to above),
(f) conjugate (referring to above) of Ren Xuan carrier protein and Type B hemophilus influenza (Hib) capsular saccharides,
(g) conjugate of Ren Xuan carrier protein and A type meningococcus (MenA) capsular saccharides or C type meningococcus (MenC) capsular saccharides wherein one or both (referring to above) and
Second container comprises:
(2A) conjugate of (a) carrier protein and A type meningococcus (MenA) capsular saccharides, C type meningococcus (MenC) capsular saccharides, W type meningococcus (MenW) capsular saccharides and/or Y meningococcus (MenY) capsular saccharides (referring to the combination of the various Men sugar of the present invention above) and
(b) conjugate of Ren Xuan carrier protein and Type B hemophilus influenza (Hib) capsular saccharides; Or
(2B) conjugate of (a) optional carrier protein and Type B hemophilus influenza (Hib) capsular saccharides and
(b) conjugate of Ren Xuan carrier protein and salmonella typhi Vi sugar.
What described test kit was optional can comprise the 3rd container, and it comprises:
(3) (a) optional hepatitis B surface antigen
(b) conjugate of Ren Xuan carrier protein and salmonella typhi Vi sugar
Described in both cases container all can also comprise HepA antigen and/or MenB antigen and/or RTS, S and/or streptococcus pneumoniae antigen.
In both cases, same antigen should not be in two containers and all exists.
In one embodiment, first container except component a), b), c), d), also have component e), f), g), e)+f), e)+g), f)+g) or e)+f)+g).
In one embodiment, the vaccine in first container can be a liquid, and the vaccine in second container can be liquid or freeze dried (for example having known stabilising carriers such as sucrose or trehalose).
The container of described test kit can be packed separately, or optional packaging together.In one embodiment, described test kit is provided for using a series of description of vaccine in two or more containers.
In one embodiment, when the container in the test kit comprises certain glycoconjugate, in other containers of this test kit, there is not identical conjugate.
The inventor believes that the test kit that provides in the above described manner is advantageously in the best way with the immune system of various antigen presentations to the host.Described test kit provides the immune host's of the best method to the medical practitioner; this method has following one or more advantage: to whole antigenic protection effects, minimum reactionogenicity, minimum carrier suppress to disturb; minimum adjuvant/antigen disturbs, or minimum antigen/antigen disturbs.Use minimum number (2 times) just to use in this way and can realize these targets, optional occurs in when once seeking medical advice together.
In one embodiment, vaccine in first and second containers is used (described in hereinafter " using of vaccine of the present invention ") simultaneously in different sites, in a selectivity embodiment, inventor's imagination can be mixed the inclusions in first and second containers (optional faces with preceding), uses as single vaccinating agent then.
Prepare vaccine of the present invention
The present invention also provides a kind of method for preparing bacterin preparation, comprises the step with vaccine component and pharmaceutically acceptable mixed with excipients.
In one embodiment of the invention, the purposes of vaccine described herein at the medicine that is used for treatment of diseases or prevention is provided, and described disease is by poliovirus and optional bordetella pertussis, clostridium tetani, diphtheria corynebacterium, hepatitis B virus, hemophilus influenza, A type meningococcus, C type meningococcus, W type meningococcus, Y type meningococcus, the infection of salmonella typhi, hepatitis A or hepatitis A causes.
In another embodiment of the invention, provide vaccine of the present invention to be used for the purposes of the medicine of treatment of diseases or prevention in preparation, described disease is by poliovirus and optional bordetella pertussis, clostridium tetani, diphtheria corynebacterium, hepatitis B virus, hemophilus influenza, A type meningococcus, C type meningococcus, W type meningococcus, Y type meningococcus, the infection of salmonella typhi, hepatitis A or hepatitis A causes.
In addition, also provide a kind of method of immune human host resist the disease, described disease is by poliovirus and optional bordetella pertussis; clostridium tetani; diphtheria corynebacterium, hepatitis B virus, hemophilus influenza; A type meningococcus; C type meningococcus, W type meningococcus, Y type meningococcus; salmonella typhi or hepatitis A cause that this method comprises the vaccine of the present invention of using immunoprotection dosage to the host.
Antigenic amount is through selecting, can protecting the amount of replying and do not have remarkable adverse side effect by induction of immunity in typical vaccine in every kind of vaccine dose.This amount is will be according to the specific immune that uses former and how to be presented and different.An embodiment, every dosage will comprise the sugar of 0.1-100 μ g, every in another embodiment dosage will comprise 0.1-50 μ g, and every dosage will comprise 0.1-10 μ g in further embodiment, and still every in another embodiment dosage will comprise 1-5 μ g sugar.
In one embodiment, the content range of proteantigen is 1-100 μ g in the described vaccine, and in another embodiment, the content range of proteantigen is 5-50 μ g in the described vaccine, in further embodiment, the content range of proteantigen is 5-25 μ g in the described vaccine.
The vaccine product general description is in Vaccine Design (vaccine design) [" The subunit andadjuvant approach " (eds Powell M.F.﹠amp; Newman M.J.) (1995) PlenumPress New York].Fullerton has described the intravital parcel of lipid (United States Patent (USP) 4,235,877).For example people (United States Patent (USP) 4,474,757) such as Likhite (United States Patent (USP) 4,372,945) and Armor disclose albumen and macromolecular puting together.People such as Dalsgaard (1977, Acta Vet Scand.18:349) disclose the use of Quil A.3D-MPL is available from Ribi immunochem, USA, and be disclosed in GB Patent Application No. 2220211 and United States Patent (USP) 4,912,094.QS21 is disclosed in United States Patent (USP) 5,057,540.
In another embodiment of the invention, a kind of polyvalent vaccine is provided, it comprises the poliovirus (IPV) and the optional deactivation whole cell pertussis bacillus (Pw) of deactivation of the present invention, tetanus toxoid (TT), diphtheria toxoid (DT), the conjugate of carrier protein and Type B hemophilus influenza capsular saccharides (optional the puting together of Hib-) with TT, DT or CRM197, the amount of conjugate is 1-8 μ g in the initial vaccine of wherein every 0.5mL dosage, and the immunogenicity of described conjugate equals or be enhanced to surpass this based composition that comprises the greater amount conjugate.Choose wantonly, can also comprise hepatitis B surface antigen.
In one embodiment, the amount of conjugate is less than 10 μ g (sugar in the described conjugate) in the initial vaccine of every 0.5mL dosage, the amount of conjugate is 1-7 in another embodiment, the amount of conjugate is 2-6 μ g in another embodiment, or is about 2.5,3,4 or 5 μ g in further embodiment.
Should understand some component such as the DTPw component, can combination separately before the HBsAg that adds absorption or other components.
The method for preparing vaccine of the present invention also is provided, and it comprises the step with 1 type IPV, 2 type IPV and/or 3 type IPV and pharmaceutically acceptable mixed with excipients.Utilize the exemplary steps of the initial vaccine of other antigen preparation the present invention to add the IPV component in the mixture of D and T component, promptly the DT component is mixed with the IPV component.This order by merging allows to regulate the ionic strength and/or the pH (for example pH＜7) of compositions before adding Pa or Pw component.Usually, add preadsorption earlier to AlPO 4On HB (if it is included in the compositions), add preadsorption then to Al (OH) 3Or AlPO 4On DT, add preadsorption subsequently to Al (OH) 3Or AlPO 4On TT, add optional preadsorption then to Al (OH) 3On IPV, regulate pH conveniently to pH5.9-7.2 for example, or pH6-7, or pH6.2-6.8, or pH6.4-6.6, add preadsorption then to AlPO 4On Pw.Choose wantonly, can add Hib, Vi, MenA, MenC, MenW, Men Y, MenB and/or HepA antigen at any point of this step.In one embodiment, can before pH regulator, add Hib, Vi, MenA, MenC, MenW, Men Y, MenB and/or HepA antigen.In one embodiment, one or more antigens of the present invention are adsorbed onto on aluminum phosphate or aluminium hydroxide or the two the mixture.In another embodiment, antigen of the present invention mixes with pharmaceutically acceptable excipient and/or adjuvant.
In one embodiment, prepare vaccine combination of the present invention in the following order: the HBsAg that adds preadsorption, succeeded by the diphtheria toxoid of preadsorption,, before the Pw that adds preadsorption, regulate pH then to about 6.5 succeeded by the tetanus toxoid and the IPV of preadsorption.
In another embodiment, prepare vaccine combination of the present invention in the following order: add the HBsAg of preadsorption, succeeded by IPV, succeeded by the HBsAg of preadsorption, succeeded by the diphtheria toxoid of preadsorption, before the Pw that adds preadsorption, regulate pH to about 6.5.
Usually, combined vaccine composition that can preparation as described below any aspect according to the present invention: with IPV, DTPw, HepB, MenA, MenC, MenW, MenY, MenB, Vi, hepatitis A or other component preadsorption to suitable adjuvant, especially aluminium hydroxide or aluminum phosphate or the two mixture.After the time that the stable absorption of enough respective components complete sums is provided, the different component of combination under appropriate condition.With before the DTPw vaccine mixes, Hib, Vi, MenA, MenC, MenW and/or MenY conjugate can be adsorbed onto or can not be adsorbed onto on the aluminium adjuvant salt.
In one embodiment, (for example between 19 ℃ to 27 ℃, or 23 ± 4 ℃) prepares vaccine of the present invention between 15 ℃ to 30 ℃.
Using of vaccine of the present invention
The invention provides a kind of method that in mammal, excites immunne response, comprise the step of the vaccine of the present invention of using effective dose.Described vaccine can be preventative using (being prevention infection).Described immunne response is protectiveness preferably, and preferably comprises antibody.Described method can excite booster response.
Behind primary vaccination, what the experimenter can accept sufficient distance once or for several times strengthens (follow-up) immunity.Quantitatively treatment can be single dose scheme or multiple dose scheme.Multiple dose can be used for initial immunity scheme and/or booster immunization scheme.Can follow the booster dose scheme after the predose scheme (it can carry out 1 year of life).Just exempt from the inoculation between (for example 4-16 is between week) and just exempt from and strengthen between suitable period can determine according to routine.
In one embodiment, mammal is the people.When vaccine was used for preventative purposes, the people is child's (for example begining to learn the baby who walks) or juvenile preferably; When being used for the treatment of property of vaccine purposes, the people preferably is grown up.Expection is used for child's vaccine also can use to the adult, for example is used for evaluate safety, dosage, immunogenicity or the like.
Bacterin preparation of the present invention can be used to protect or treat easily infected mammal, by directly using described vaccine to the patient.Directly send and can realize in the following manner: parenteral (intramuscular, intraperitoneal, Intradermal, hypodermically, intravenous, or to the intercellular substance of organizing); Or by rectum, oral, vagina, part, transdermal, intranasal, eye, ear, pulmonary or other mucosal administrations.In one embodiment, use to thigh or upper arm by intramuscular injection.Injection can be passed through syringe needle (for example hypodermic needle), but selectively also can use the needleless injection.Typical intramuscular dosage is 0.5mL.
Bacterial infection influences each zone of health, and therefore compositions of the present invention can be prepared to various forms.For example, described compositions can be prepared as injectable, for example liquid solution or suspension.Described compositions can prepare and be used for pulmonary administration such as inhaler, utilizes fine powder or spray.Described compositions can be prepared as suppository or vaginal suppository.Described compositions can be produced and be used for nose, ear or eye is used, such as spray, drop, gel or powder (referring to for example Almeida ﹠amp; Alpar, 1996, J Drug Targeting, 3:455; People such as Bergquist, 1998, APMIS, 106:800).Successful DTP vaccine intranasal administration be in the news (people such as Ryan, 1999, Infect.Immun., 67:6270; People such as Nagai, 2001, Vaccine, 19:4824).
In one embodiment, the vaccine of first and second (and under the suitable situation the 3rd) container is administered to different loci simultaneously, and at one optionally in the embodiment, the inventor imagines the inclusions of first and second containers can mix (optional faces with preceding), then as single vaccine administration.
The present invention can be used to cause general and/or mucosal immunity.
A kind of method that detects the therapeutic treatment effect relates to monitors bacterial infection after using the present composition.A kind of method that detects the prophylactic treatment effect relates to the anti-described antigenic immunne response of monitoring behind applying said compositions.By using the immunogenicity that can measure them for test experimenter (for example big child of the 12-16 month, or animal model-WO 01/30390) compositions of the present invention, immune parameter then settles the standard.Usually about 4 weeks are measured these immunne response behind applying said compositions, and with applying said compositions before the value measured compare.Be not to estimate real protection effect in the patient, it is known being used to estimate the standard animal of DTP vaccine effect related with external model and protection.
In all cases, the inventor expect that this paper term " comprises ", " comprising " and " containing " can be chosen wantonly respectively with term " by ... form ", " by ... constitute " and " by ... composition " replacement.This does not change the common implication of these terms, and it aims to provide the basis of described replacement, rather than makes their implications identical.
The list of references and the publication of all references all are hereby incorporated by.
Embodiment
The embodiment that provides just is used for illustration purpose, rather than is used to limit the scope of the invention.
Embodiment 1: to the test of low dosage IPV preparation
For all preparations of embodiment 1, except IPV (it is added but not absorption), before preparation, make antigen absorption by adding aluminum salt.
Following table shows the adsorption method of D, T, Pw and HBsAg.
AlPO 4
|
D(7.5Lf/0.075mg Al 3+)
|
In stirring at room 15 until 20 minutes.
|
Regulate pH to pH 5.1+/-0.1
|
In stirring at room 15 until 20 minutes.
|
Proofread and correct pH 5.1+/-0.1
|
In stirring at room 15 until 45 minutes.
|
37 ℃+/-1 ℃ ripening 7 days+/-8 hours does not have and stirs (glass container)
Stirring (rustless steel container) is arranged
|
In stirring at room 15 until 45 minutes.
|
Regulate pH to pH 6.1+/-0.1
|
In stirring at room 15 until 20 minutes.
|
Proofread and correct pH 6.1+/-0.1
|
Preserved minimum 7 days at+2/+8 ℃ before the preparation
Figure A200780041465D00381
Table 1. is used for the preparation method of diphtheria toxoid absorption
Al(OH) 3
The SUPERFOS type
|
T(3.25Lf/0.070mg Al 3+)
|
Stirring at room 15 minutes until 20 minutes.
|
Be adjusted to pH 6.1+/-0.1
|
Stirring at room 15 minutes until 20 minutes.
|
Proofread and correct pH6.1+/-0.1
|
Stirring at room 16 hours until 24 hours.
|
NaCl 1500mM.(ad.150mM)
|
Stirring at room 15 minutes until 45 minutes.
|
Be adjusted to pH 6.1+/-0.1
|
Stirring at room 15 minutes until 20 minutes.
|
Proofread and correct pH6.1+/-0.1
|
Preserve least fourteen days at+2 ℃ /+8 ℃ before the preparation.
Figure A200780041465D00391
Table 2. is used for the preparation method of tetanus toxoid absorption
AlPO 4
0.17mg Al 3+/d
(Brenntag)
|
Regulate pH to pH6.5+/-0.1
|
Stirring at room 15 minutes until 20 minutes.
|
Proofread and correct pH 6.5+/-0.1
|
Pw
20IOU/d
|
Stirring at room 15 minutes until 45 minutes.
|
Measure pH
|
+ 2 ℃ of-+8 ℃ of preservations
Figure A200780041465D00401
Table 3. is used for the preparation method of Pw absorption
HBsAg
10μg
|
Al 3+ 0.20mg
AlPO4
Stirring at room 15 minutes until 30 minutes.
|
Regulate pH to pH 5.3+/-0.1
|
Stirring at room 15 minutes until 30 minutes.
|
Proofread and correct pH to pH 5.3+/-0.1
|
In stirring at room 20 hours+/-4 hours (absorption)
|
Regulate pH to pH6.1+/-0.1
|
Stirring at room 15 minutes until 30 minutes.
|
Proofread and correct pH to pH 6.1+/-0.1
|
In room temperature preservation 14 days (ripening)
|
2 ℃ of-8 ℃ of preservations
Table 4. is used for the preparation method of HBsAg absorption
Detected several different preparations:
● the combination of diphtheria toxoid, tetanus toxoid, the full cell of pertussis and hepatitis B surface antigen: DTPwSF-HB prepares according to preparation method 1 (table 5) as with reference to (DTPwSF represents that it is the preparation that does not contain thimerosal).
● GlaxoSmithKline Biologicals S.A. product
Figure A200780041465D0042144611QIETU
(IPV is independent non-adsorbable) as the not absorption reference of standard dose, prepares according to preparation method 2 (table 5).
● the combination of diphtheria toxoid, tetanus toxoid, the full cell of pertussis, hepatitis B surface antigen and inactivated poliovirus: in Pw forward direction DTPwSF-HB-IPV, add IPV, prepare according to preparation method 3 (table 5).
● the combination of diphtheria toxoid, tetanus toxoid, the full cell of pertussis, hepatitis B surface antigen and inactivated poliovirus: just after T absorption, in DTPwSF-HB-IPV, add IPV.This adding method allows IPV to be adsorbed onto on the Al (OH) 3.This vaccine is prepared according to preparation method 4 (table 5).
Placebo only comprises aluminum salt, IPV and other antigenic buffer.Because IPV is unique antigen of this placebo, there is not absorption competition.Therefore, IPV adsorbs fully.This vaccine is prepared according to preparation method 5 (table 5).
Utilize the vaccine of preparation method 2,3,4 and 5 preparations to be prepared as the IPV dosage range between 12.5% and 100% of the standard I PV of 40/8/32IU/0.5mL dosage.
Step preparation method 1:DTPwSF-HB
1 interpolation water for injection is that 0.5mL2 interpolation NaCl 1.5M is that 150mM3 adds 115 μ g Al to final concentration to the final dose volume 3+(AlPO 4Form) 4 HBsAg5 that the add 10 μ g absorption diphtheria toxoid 6 that the add 7.5Lf absorption tetanus toxoid 7 that adds 3.25Lf absorption stirs 8 and regulates pH and stir 10 to 6.5+/-0.19 and add the Pw11 stirring 12 of 20IOU absorption+2 to+8 ℃ of preservations
Figure A200780041465D00431
Figure A200780041465D00432
Figure A200780041465D00441
The preparation method of the every 0.5mL dosage of table 5.
For preparation method 1 preparation: HBsAg, D and T are adsorbed onto AlPO respectively individually 4, AlPO 4And Al (OH) 3On.Described 3 kinds of antigens are added continuously to and comprise water, NaCl and free AlPO 4Suspension in.This mixture was stirred 60-75 minute.Then before the Pw that adds absorption with pH regulator to 6.5.
For preparation method 3 preparations, the antigen of 3 kinds of absorption is added continuously to comprises water, NaCl and free AlPO 4Suspension in.Before adding IPV, this mixture was stirred 60-75 minute.Then before adding Pw antigen with pH regulator to 6.5.
For preparation method 4 preparations, T antigen is adsorbed onto Al (OH) 3On.The T antigen of preadsorption is added in the suspension that comprises water and NaCl, is 1,2 and 3 type IPV then.Adding free AlPO 4Before this mixture was stirred 60-75 minute.Add the HBsAg of preadsorption then, succeeded by the D antigen of preadsorption, subsequently with this mixture restir 60-75 minute.Then before adding Pw antigen with pH regulator to 6.5.
At last owing to the simple and easy preparation method 3 of selecting for preparing, because this experimental procedure only relates to a whipping step.In the process of preparation vaccine, do not use thimerosal, it is not added in the final vaccine product yet.
Figure A200780041465D00461
The Polio that measures in the rat by serum neutralization test renders a service
Measure the effectiveness of vaccine by serum neutralization test in intramuscular inoculation rat (Sprague-Dawley (OFA) or anything be the strain of checking earlier) back.Give 10 not dilutions of group intramuscular inoculation (0.5mL) test specimen of immune healthy rat, be dissolved in the reference substance of phosphoric acid brine buffer solution, or diluent (phosphoric acid brine buffer solution).10 rats of inoculation diluent are used as negative control.20 to 22 days (between the duration of immunity) in inoculation back with every animal deep anaesthesia, collected blood by cardiac puncture then.With blood sample centrifugal (at about 800g), and serum analysis.
Serum neutralization test:
By at 30 minutes inactivated serums of 56 ℃ of incubations.Utilize suitable diluent media in microplate, to prepare 3 serial dilution things of serum, every kind of a kind of poliomyelitis type of correspondence.For 3 kinds of poliovirus types, in the serum dilution, add the virus of scheduled volume.Described 3 kinds of viral suspensions dilute according to their corresponding titres.Final dilution is called as " work dilution ".Add every kind of work dilution to corresponding microplate.Then with plate sealing, 37 ℃ ± 1 ℃ incubation 16 hours.Add the Hep-2 cell then, microplate was 37 ℃ ± 1 ℃ incubation 7 days.After Coomassie blue stain, utilize the cellular pathogenic effect (CPE) of inverted microscope record virus.
The existence of poliomyelitis antibody suppresses the growth of virus and the appearance of corresponding CPE.The final dilution inverse of poliomyelitis virus titer (1,2 and 3 type) any CPE that is equal to nothing.
In every group, record has the animal of neutralizing antibody, and measures in each blood serum sample the antibody titer at dissimilar polioviruses.NAT is represented with the log2 of the inverse of the high dilution (suppressing the cytopathic effect of poliovirus to the Hep-2 cell fully) of blood serum sample.Measure the geometric mean titer (GMT) of each dilution factor and every kind of Virus Type in every group of rat then.
For every type virus, also in 50% rat (ED50), induce the vaccine dilution factor of neutralizing antibody and D antigen amount subsequently by probit analysis calculating.ED50 represents with D antigen unit.
For quantitatively (normally with respect to the reference vaccine
Figure A200780041465D00471
But also can be the DTPaHBIPV vaccine such as
Figure A200780041465D00472
Effectiveness, in multiple dose test, detect relative effectivenes (RP), it is defined as the ratio that two kinds of dose,equivalents are replied.In the method, according to Finney at (Statistical Method in Biological Assay (statistical method in the bioanalysis), Charles Griffin ﹠amp in 1978; Company Ltd, London, 1978) the parallel lines analytic process of describing calculates the effectiveness of experimental vaccine.
Detect the poliomyelitic effectiveness of 1,2 and 3 types by ELISA
Detect poliomyelitis effectiveness by ELISA and adopt a step or two-step method to carry out, this depends on respectively measures to the IPV of first beginning and end absorption or to the vaccine of preparation:
1. the desorbing (be used for detecting the D antigen unit of preparation vaccine-in the IPV antigen stock that detects not absorption, be unwanted) of finally adsorbing vaccine;
2. be used for quantitative desorbing and do not adsorb vaccine and/or the ELISA of poliomyelitis stock solution D antigenic content test
Desorption procedure
With the absorption vaccine after centrifugal 10 minutes in the test,, carry out 3 successive desorbings by in precipitate, adding the desorbing phosphate buffer, mixing and be incorporated in the room temperature incubation.For the first time and for the second time desorb cycle is 2 hours, and the incubation period of Ti Quing is to spend the night under the room temperature for the third time.To compile from the gleanings that extracts for 3 times, and with not containing Ca and Mg but the phosphate buffer (PBS) that contains bovine serum albumin (BSA) and Tween 20 dilute.
According to the quantitative 3 kinds of poliovirus antigens of ELISA as described below.
D antigen by ELISA is quantitative:
Specificity rabbit poliomyelitis virus (1,2 or 3 type) IgG with carbonate buffer (pH 9.6) dilution wraps by microtitration plate, and is incubated overnight at 4 ℃.After the cleaning, add saturated solution (phosphoric acid brine buffer solution w/o Ca and Mg+1% BSA).The serial dilution thing of blank (PBS) and vaccine sample and make not the adsorption criteria product by oneself by duplicate interpolation.Make 1, the 2 and 3 type antigens that the accurate goods of 3 price cards comprise demarcation by oneself.Calibration object be European Pharmacopoeia biology with reference to (European Pharmacopoeia Biological reference, EPBRP).
For all subsequent steps, microtitration plate cleans then 37 ℃ of incubations 1 hour 30 minutes.Add rabbit poliomyelitis virus (1, the 2 or 3 type) IgG that puts together peroxidase, it dilutes with the phosphate buffer (w/o Ca and Mg+Tween 20) that comprises BSA.Add substrate solution, it comprises the tetramethyl benzidine that is dissolved in dimethyl sulfoxide (DMSO) and with comprising 0.003% H 2O 2Acetate buffer solution dilution, in the dark incubation 15-30 minute then.Add then and comprise H 2SO 4Blocking solution.In 1 hour, utilization is arranged on 450nm and reference is read the optical density (O.D.) in every hole at the spectrometer of 620nm.
Obtain standard curve by O.D. value mapping, according to the D antigen concentration in this standard curve calculating test specimen to standard antigen concentration.
As replenishing of the effectiveness that ELISA is obtained, can pass through completeness method (completeness method) and detect any not IPV antigen of absorption:
Completeness by unconjugated 1,2 and 3 type Polio in the absorption of ELISA detection and adjuvant
Carry out continuous centrifugal twice.Collect supernatant then, on microplate, detect undiluted thing in duplicate by ELISA.Specificity rabbit poliomyelitis virus (1,2 or 3 type) IgG with carbonate buffer (pH9.6) dilution wraps by microtitration plate, and is incubated overnight at 4 ℃.After the cleaning, add saturated solution (phosphoric acid brine buffer solution w/o Ca and Mg+1% BSA).Blank (PBS), go up the serial dilution thing of cleer and peaceful vaccine sample and make not the adsorption criteria product by oneself by duplicate interpolation.
For all subsequent steps, microtitration plate cleans then 37 ℃ of incubations 1 hour 30 minutes.Add rabbit poliomyelitis virus (1, the 2 or 3 type) IgG that puts together peroxidase, it dilutes with the phosphate buffer (w/o Ca and Mg+Tween 20) that comprises BSA.Add substrate solution, it comprises the tetramethyl benzidine that is dissolved in dimethyl sulfoxide (DMSO) and uses the acetate buffer solution dilution that comprises 0.003% H2O2, in the dark incubation 15-30 minute then.Add the blocking solution that comprises H2SO4 then.In 1 hour, utilization is arranged on 450nm and reference is read the optical density (O.D.) in every hole at the spectrometer of 620nm.
If be higher than 0.1 if the average OD of sample is higher than the average OD of barren average OD value+3 standard deviations and sample, then completeness is considered to male (antigen in the supernatant).
For male completeness, measure antigenic content according to the ELISA method that second step described in " detecting 1,2 and 3 type Polio by ELISA renders a service ".
Measure international opacity unit (International Opacity Unit, method IOU)
Can utilize optics IRPO (international reference preparation of opacity) standard solution or determine cell concentration (IOU) by the absorbance measuring value of 660nm.
Utilize following " specified opacity " equation to determine the opacity of individual plant suspension (Single StrainSuspension) then:
AO＝LO/Ko×CO；
The specified opacity of AO=wherein, LO=live opacity, the opacity of KO=deactivation gleanings and the opacity of CO=concentrate of gleanings.
The result
The Polio that measures in the rat by serum neutralization test according to the 40:8:32 dosage of standard renders a service
Experimentize to determine the effectiveness of 1,2 and 3 type IPV.The results are shown in following table 8 (in this article, 1 of 40:8:32D antigen unit, 2 and 3 type IPV equal 100%IPV dosage respectively).
Figure A200780041465D00501
The effectiveness of table 8.3 kind of different bacterin preparation kinds 1,2 and 3 type IPV.
The IPV that DTPwSF-HB-IPV preparation (100%IPV) shows renders a service than better with reference to Poliorix, and similar or better than it with reference DTPaHBIPV.
The evaluation that IPV renders a service under the IPV dosage reduction condition
Detect by method in the aforesaid external and body and to render a service.
For two kinds of preparations of preparation method 3 and 4, the effectiveness of the reduction dosage IPV that obtains by Elisa in vitro detection, and compare with reference DTPaIPVHB, as shown in table 9.For two batches of every kind of preparation of preparation method 3 check.
For every kind of preparation, calculating recovery percentage ratio according to the antigenic content of taking from IPV stock solution (is 40/8/32 for the preparation that comprises 100% IPV for example; The preparation that comprises 50% IPV is 20/8/16; The preparation that comprises 25% IPV is 10/4/8; For the preparation that comprises 12.5% IPV is 5/2/4)
Figure A200780041465D00511
Table 9 shows that for all IPV dosage absorption completenesses be similar.1 type and 3 types are that (17%-74%) inhaled in strong solution, and 2 types are good adsorption.For all IPV dosage, 3 types all is good adsorption for placebo.Described absorption is with similar with reference to the absorption of vaccine to DTPaIPVHB.
There is variation in the IPV completeness, because the completeness quantitative approach is not suitable for DTPwHB IPV preparation and lower IPV concentration (＜40/8/32D antigen unit/0.5ml).
At two kinds of preparations of preparation method 3 and 4, by with the reference preparation relatively, detect in vivo the IPV that reduces dosage relative effectivenes (with relatively the representing of reference poliorix vaccine), as illustrated in fig. 1 and 2.For two batches of every kind of preparation of preparation method 3 check.
Fig. 1 shows that the IPV that the effectiveness of the DTPwSF-HB-IPV that contains 100% IPV is a bit larger tham among the DTPaHBIPV renders a service.Observing IPV from the DTPwSF-HB-IPV 50% of preparation method 3 preparations renders a service and is similar to DTPaHBIPV 100%.The IPV of the DTPwSF-HB-IPV 25% of preparation method 3 renders a service and is lower than slightly
Figure A200780041465D0052145050QIETU
Also find 12.5% the IPV effectiveness of IPV underdosage to obtain.
Fig. 2 shows that for the preparation of preparation method 3 and the preparation of preparation method 4, IPV renders a service similar.Show that also placebo renders a service better trend than DTPwSF-HB-IPV.
Therefore these data acknowledgements reduce the effectiveness that the IPV of dosage is enough to obtain in vivo.
Embodiment 2: the feasibility of not using thimerosal in vaccine of the present invention
Preservative efficacy test (PET) can detect the antimicrobial acivity of experimental vaccine.This test comprises:
In the final container step of bacterin preparation, utilize the appointment inoculation of suitable microorganism, attack described bacterin preparation,
Preserve the described preparation of being inoculated at assigned temperature
Take out sample at interval from container at official hour, and to taking out the organism counting in the sample.
The PET test procedure is described in European Pharmacopoeia (5.1.3) and USP (＜51 〉).Instruct according to these, compare, estimate antimicrobial acivity by the standard that the reduction and the following table (table 7) of live microbial amt are mentioned
Figure A200780041465D00531
Table 7.EP and USP standard
Nr *: do not reclaim
Ni *: do not increase
Embodiment 3:Hib component is renderd a service IPV and in time to the influence of IPV stability
According to the relative effectivenes of embodiment 1 described detection IPV,, and estimate IPV stability in time under the different IP V dosage condition with the influence of determining that the Hib component is renderd a service IPV.The vaccine that is studied is DTPwHBIPV (40-8-32), contain the DTPwHBIPV of reconstruction and preserved 8 months, DTPwHBIPV (20-4-16), contain the DTPwHBIPV (20-4-16) that rebuilds Hib and preserved 8 months, DTPwHBIPV (20-4-16) also preserved 8 months, DTPwHBIPV (10-2-8) and contain the DTPwHBIPV (10-2-8) that rebuilds Hib and preserved 8 months.(Fig. 3 a) or the RP value of Poliorix (Fig. 3 b) with respect to DTPaIPVHB (Pediarix) in measurement.Find that the Hib component is to the not influence of IPV effectiveness.Discovery still is held (Fig. 3) at the relative effectivenes of 8th month IPV.
Embodiment 4:AlPO 4/ Al (OH) 3Ratio is to the absorption of optics aspect, D and T and the influence of IPV effectiveness
Utilize the variation of aluminum composition to be prepared.
Preparation DTPw SF-HB-IPV comprises 630 μ g aluminum usually: 560 μ g Al 3+(AlPO4 form), 70 μ g Al 3+(Al (OH) 3Form).Use the absorption of aluminum salt D, T, Pw and HbsAg.During preparation add free AlPO 4115 μ g Al 3+
Utilize the free Al of following ratio 3+Be prepared:
Al(OH)3 μg Al3+ AlPO4 μg Al3+
Batch
1 0 115
Batches 2 23 92
Batches 3 69 46
Batches 4 46 69
Batches 5 92 23
Batches 6 115 0
Table 10.AlPO4/Al (OH) 3 ratios
Step preparation method 3:DTPw SF-HB-IPV
It is that 0.5mL2 interpolation NaCl1.5M is that 150mM3 is according to different Al (OH) to final concentration that 1 interpolation water for injection reaches the final dose volume 3/AlPO 4Ratio is added 115 μ g Al 3+The tetanus toxoid 7 that the diphtheria toxoid 6 that 4 HBsAg5 that add 10 μ g absorption add 7.5Lf absorption add 3.25Lf absorption stirs 8 dosage according to 40/8/32IU to be added IPV9 and stirs 10 and regulate pH and stir 12 to 6.5+/-0.111 and add the Pw13 stirring 14 of 20IOU absorption+2 to+8 ℃ of preservations
The preparation method of table 11.DTPwHB-IPV
The viewing optics aspect, the ratio until 69/46 still can obtain acceptable aggregation.
Utilize identical preparation method and between conventional IPV dosage 0 and 100% between the IPV dosage range be prepared.
Measure the percentage ratio of D and the absorption of T toxoid by ELISA.Detect the stability of absorption after 7 days 37 ℃ of processing.The results are shown in table 12 and 14.
Figure A200780041465D00551
Table 12. contains the percentage ratio of D toxoid desorbing among the DTPwHB-IPV of IPV dosage range
Figure A200780041465D00552
The percentage ratio that table 13. contains T toxoid desorbing among the DTPwHB-IPV of IPV dosage range is IPV absorption then.Detect the stability of absorption after 21 days 25 ℃ of processing.
Figure A200780041465D00561
Table 14. contains the percentage ratio of IPV desorbing among the DTPwHB-IPV of IPV dosage range
Al in the described preparation (OH) 3The increase of content can promote the absorption of D, T and IPV.
Utilize 46/69 Al (OH) 3/ AlPO 4Ratio obtains better absorption ratio.
In this ratio:
■ T and D are adsorbed on the 0th day (T0) and finish.Desorbing after 37 ℃ of 7 days accelerated stability research shows desorbing for D＜20%, desorbing for T＜30%.
Every kind of IPV type of ■ all adsorbs.The desorbing of 3 types occur in 25 ℃ the 21st day.
Detect preparation in vivo, and compare with Tetravac, Poliorix and DTPaIPV vaccine with 46/69 ratio.
Figure A200780041465D00571
Efficacy results in table 15. body
Described DTPw-HB-IPV preparation does not have significant difference (ED50).DTPaHBIPV, Tetravac and Poliorix obtain similar result, all are inferior to DTPw-HB-IPV preparation (all preparations except 2 types all are equal to).
Embodiment 5: contain and reduce the clinical identification of IPV Research on dose with the DTPw-HBV-IPV/Hib vaccine
In the II phase, the research 3 kind different preparations relative commercialization DTPw-HBV/Hib of DTPw-HBV-IPV/Hib vaccine and immunogenicity, reactionogenicity and the safety of IPV vaccine coupling of plan feasibility study to estimate GSK Biologicals.
● Indication/colony
First week at life is given healthy babies initial immunity, diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and b type hemophilus influenza disease.
Seminar:
DTPw-HBV-IPV (standard dose)/Hib vaccine
DTPw-HBV-IPV (standard dose 49%)/Hib vaccine
DTPw-HBV-IPV (standard dose 26%)/Hib vaccine
DTPw-HBV/Hib+IPV vaccine s
● Common main target:
Common main target will be estimated in a continuous manner: promptly have only and just estimate the second and the 3rd target when last target is met.
√ is in order to prove after the primary vaccination process one month, and with regard to regard to the antibody response of 3 kinds of poliovirus types, DTPw-HBV-IPV (standard dose)/Hib vaccine is with respect to the non-pessimum of the IPV vaccine of using altogether with the DTPw-HBV/Hib vaccine.
If with regard to every kind serum protective rate in 3 kinds of poliovirus types; (DTPw-HBV/Hib+IPV deducts DTPw-HBV-IPV (standard dose)/Hib)≤10% to the upper limit of asymptotic 95% CI of the standardization of each group difference, then reaches the target of non-pessimum.
√ is in order to prove after the primary vaccination process one month, with regard to regard to the antibody response of 3 kinds of poliovirus types, DTPw-HBV-IPV (standard dose 49%)/Hib vaccine is with respect to the non-pessimum of the IPV vaccine of using altogether with the DTPw-HBV/Hib vaccine.
If with regard to every kind serum protective rate in 3 kinds of poliovirus types; (DTPw-HBV/Hib+IPV deducts DTPw-HBV-IPV (standard dose 49%)/Hib)≤10%, then reach the target of non-pessimum to the upper limit of asymptotic 95% CI of the standardization of each group difference.
√ is in order to prove after the primary vaccination process one month, with regard to regard to the antibody response of 3 kinds of poliovirus types, DTPw-HBV-IPV (standard dose 26%)/Hib vaccine is with respect to the non-pessimum of the IPV vaccine of using altogether with the DTPw-HBV/Hib vaccine.
If with regard to every kind serum protective rate in 3 kinds of poliovirus types; (DTPw-HBV/Hib+IPV deducts DTPw-HBV-IPV (standard dose 26%)/Hib)≤10%, then reach the target of non-pessimum to the upper limit of asymptotic 95% CI of the standardization of each group difference.
● By-end:
Immunogenicity
With regard to regard to the replying of all vaccine antigens, the DTPw-HBV/Hib that uses together compares with the IPV vaccine, estimates the immunogenicity of DTPw-HBV-IPV/Hib candidate vaccine.
Reactionogenicity
According to the symptom of demand, the symptom and the serious adverse events of positive appeal, the reactionogenicity of evaluation study vaccine and safety.
● Vaccination regimen
6, the 3 dosage primary vaccination schemes in 10 and 14 ages in week.All experimenters accept the timely inoculation (birth dose) of hepatitis B.
● Country:
Philippine
● Blood sampling:
Before the inoculation and inoculation back 3
● Bacterin preparation:
Figure A200780041465D00601
Table 16. bacterin preparation
Antigenic preadsorption
The DTPw-HBV-IPV preparation has made up diphtheria toxoid, tetanus toxoid, 3 kinds of bordetella pertussis strains, the poliovirus (IPV) of main surface antigen (HBsAg) of the hepatitis B virus of purification (HBV) and deactivation.With before aluminum salt, sodium chloride buffer and water for injection mix, at first with these antigens (except IPV) preadsorption to aluminum salt.
The absorption of diphtheria toxoid
According to 15Lf diphtheria toxoid/0.15mg Al 3+Ratio the diphtheria concentrate of purification is adsorbed onto on the aluminum phosphate.These two kinds of components were at room temperature stirred 15 until 45 minutes.PH regulator to pH 5.1 ± 0.1, is stirred 15 then until 45 minutes.This mixture is preserved a week at 37 ℃.At room temperature stir 15 after 45 minutes, pH regulator is arrived pH 6.1 ± 0.1.With absorption concentrate+2 ℃ of-+8 ℃ of preservations at least 7 days, finally prepare the DTPw-HB-IPV vaccine then.Hereinafter Fig. 1 emphasis shows the absorption preparation method of the diphtheria stock solution of preadsorption.
The adsorption process figure of diphtheria toxoid
AlPO4
↓
D(15Lf/0.15mg Al3+)
↓
Stir 15 under the room temperature until 45 minutes
↓
Regulate and proofread and correct pH (5.1 ± 0.1)
↓
Stir 15 under the room temperature until 45 minutes
↓
37 ℃ of absorption 7 days
↓
Stir 15 under the room temperature until 45 minutes
↓
Regulate and proofread and correct pH (6.1 ± 0.1)
↓
Preserved minimum 7 days at+2 ℃ .+8 ℃ before the preparation
The absorption of tetanus toxoid
According to 3.25Lf diphtheria toxoid/0.07mg Al 3+Ratio the diphtheria concentrate of purification is adsorbed onto on the aluminium hydroxide.These two kinds of components were at room temperature stirred 15 until 20 minutes.PH regulator is arrived pH 6.1 ± 0.1.This mixture was at room temperature stirred 16 until 24 hours.Adding demarcation concentration is the sodium chloride solution (ad 150mM) of 1500mM.At room temperature stir 15 after 45 minutes, with pH regulator to 6.1 ± 0.1.With absorption concentrate+2 ℃ of-+8 ℃ of preservations at least 14 days, finally prepare the DTPw-HBV-IPV vaccine then.
The adsorption process figure of tetanus toxoid
Al(OH)3
↓
T(3.25Lf/0.07mg Al3+)
↓
Stir 15 under the room temperature until 20 minutes
↓
Regulate and proofread and correct pH 6.1 ± 0.1
↓
Stir 16 hours under the room temperature until 24 hours
↓
NaCl 1500mM(ad 150mM)
↓
Stir 15 under the room temperature until 45 minutes
↓
Regulate and proofread and correct pH (6.1 ± 0.1)
↓
Preserve least fourteen days at+2 ℃ .+8 ℃ before the preparation
The absorption of hepatitis B antigen
Aseptic Purification of HBsAg stock solution is mixed with aseptic aluminum phosphate suspension, to obtain in the final volume of about 50 μ l, to comprise per 10 μ g HBsAg, 0.2mg Al 3+The suspension of (aluminum phosphate form), 150mMNaCl.
The adsorption step of HBsAg
HBsAg(10μg/0.5ml)
↓
Al3+(0.2mg/0.5ml)(AlPO4)
↓
Stirred 15-20 minute under the room temperature
↓
Regulate and proofread and correct pH (5.3 ± 0.1)
↓
Stirred 16-24 hour under the room temperature
↓
Regulate pH to 6.1 ± 0.1
↓
Preserved 14 days under the room temperature
↓
4 ℃ of preservations
The antigenic absorption of Pw
With AlPO 4The aseptic sterile tube of transferring to of solution.Stirred this solution 5 to 10 minutes, and directly pH regulator was arrived 6.5+/-0.1 at Guan Zhongyong 1M HCl or 0.5M NaOH.Stirred this solution 15-20 minute.Proofread and correct pH (6.5+/-0.1), if necessary regulate.
Before the absorption, the gleanings (PPH) that pertussis is compiled mixed 15 minutes before use at least, PPH was added into to comprise AlPO then 4Sterile tube.Stirred described suspension at least 15 minutes under the room temperature, can at room temperature preserve and spend the night.Spend the night if this product is at room temperature preserved, it must be resuspended at least 30 minutes before the packing.Sampling is used for test.
Pw is adsorbed the stock solution branch install to aseptic vial, 2-8 ℃ of preservation.
The flow chart of Pw absorption
With AlPO 4Transfer to aseptic stainless steel tube
↓
Regulate pH to 6.5+/-0.1
↓
Stirred 15-20 minute under the room temperature
↓
Proofread and correct pH, regulate (6.5+/-0.1) if desired
↓
In aseptic stainless steel tube, add PPH
↓
Stirred at least 15 minutes under the room temperature
↓
Divide and install in the vial
↓
Preservation at the Pw of 2-8 ℃ of absorption
The final preparation of DTPW-HBV-IPV
Following completing steps:
-sodium chloride solution and water are mixed for injection, so that reach the final concentration of 150mM NaCl.
-interpolation AlPO 4To obtain the free Al of 0.115mg/ dosage 3+Concentration
-add HEF, diphtheria and the tetanus concentrate of absorption, to obtain the final concentration of 10 μ g HBsAg, 7.5Lf diphtheria toxoid and 3.25Lf tetanus toxoid in every 0.5ml dosage.
-add IPV to obtain 40/8/32 or the final concentration of 19.6/3.9/15.7 or 10.4/2.1/8.3UI/d.
Stir 60 under the-room temperature gently until 120 minutes.
-regulate pH to 6.5+/-0.1
Stir 15 under the-room temperature until 20 minutes
-correction pH:6.5+/-0.1
-add the Pw concentrate of absorption to obtain the final concentration of 20IOU in every 0.5ml dosage
Stir 15 under the-room temperature until 45 minutes
-measurement pH
-final stock solution+2 ℃ and+8 ℃ between, until filling.
The preparation flow figure of DTPw-HBV vaccine
WFI is to 0.5ml
↓
NaCl 1.5M is to 150mM
↓
AlPO4(115μg Al3+)
↓
The HbsAg 10 μ g of absorption
↓
The diphtheria toxoid 7.5Lf of absorption
↓
The tetanus toxoid 3.25Lf of absorption
↓
IPV 40/8/32 or 19.6/3.9/15.7 or 10.4/2.1/8.3UI/d
↓
Stir 60 minutes under the room temperature until 120 minutes
↓
Regulate and proofread and correct pH (6.50.1)
↓
Pw 20 IOU of absorption
↓
Stir 15 minutes under the room temperature until 45 minutes
Embodiment 6:Contain the Hib of reduction and the clinical identification that the IPV Research on dose is used the DTPa-HBV-IPV/Hib vaccine
In the II phase, the plan exploratory study with the research of estimating GSK Biologicals with the 4 kinds of different preparations relative commercialization DTPa-HBV-IPV/Hib vaccines of DTPa-HBV-IPV/Hib vaccine and immunogenicity, reactionogenicity and the safety of commercialization DTPw-HBV/Hib and the coupling of IPV vaccine.
● Indication/colony:
First week at life is given healthy babies initial immunity, diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and b type hemophilus influenza disease.
● Seminar:
DTPa-HBV-IPV (standard dose 49%)/Hib 5 μ g vaccines
DTPa-HBV-IPV (standard dose 49%)/Hib 2.5 μ g vaccines
DTPa-HBV-IPV (standard dose 26%)/Hib 5 μ g vaccines
DTPa-HBV-IPV (standard dose 26%)/Hib 2.5 μ g vaccines
The DTPa-HBV-IPV/Hib vaccine
The DTPw-HBV/Hib+IPV vaccine
● Main target:
According at the replying of PRP and 3 kinds of poliomyelitis antigens ( poliomyelitis 1,2 and 3), estimate the immunogenicity of DTPa-HBV-IPV/Hib candidate vaccine.
● By-end:
Immunogenicity
According at the replying of whole vaccine antigens, estimate the immunogenicity of full-fledged research vaccine.
Reactionogenicity
According to the symptom of demand, the symptom and the serious adverse events of positive appeal, the reactionogenicity of evaluation study vaccine and safety.
● Vaccination regimen
The 3 dosage primary vaccination schemes in 6 ages in week.All experimenters accept the timely inoculation (birth dose) of hepatitis B.
● Country:
TBC
● Blood sampling:
Before the inoculation and inoculation back 3
● Bacterin preparation:
Vaccine construction is become two parts: liquid part (DTPa-HB-IPV) and lyophilizing part (Hib).
D, T, PT, FHA, PRN and HBsAg carry out preliminary preadsorption.With water and NaCl and different antigen mixing.Stir described mixture and make it even, regulate pH.The final composition of described vaccine DTPa-HB-IPV part shows in following table.
Component Amount
The D toxoid 25Lf
The T toxoid 10Lf
PT 25μg
FHA 25μg
PRN 8μg
HBsAg 10μg
1 type IPV 40 or 19.6 or 10.4IU
2 type IPV 8 or 3.9 or 2.1IU
3 type IPV 32 or 15.7 or 8.3IU
Al 3+ 700 to 790 μ g
Table 17. is used for the composition of the DTPa-HBV-IPV of 0.5mL people's dosage
Hib is a preadsorption.The Hib of preadsorption mixes with sucrose or lactose before lyophilization.The Hib amount will be 2.5 or 5 or 10 μ g per capita doses.Aluminum content will be 30 to 120 μ g Al 3+(AlPO 4Form) per capita dose.

Claims (87)

1. vaccine that comprises 1 type poliovirus of deactivation, wherein the dosage of 1 type poliovirus of deactivation is greater than 10D antigen unit and less than 20D antigen unit.
2. vaccine that comprises 1 type poliovirus of deactivation, wherein the amount of 1 type poliovirus of deactivation is that every 0.5mL is greater than 10D antigen unit and less than 20D antigen unit.
3. vaccine as claimed in claim 1 or 2, the amount of 1 type poliovirus of wherein said deactivation are 26-49%, 30-45%, 33-40% or the 35-37% of standard 40D antigen unit dosage.
4. vaccine as claimed in claim 1 or 2, the amount of 1 type poliovirus of wherein said deactivation are 26-49%, 30-45%, 33-40% or the 35-37% of every 0.5mL standard 40D antigen unit dosage.
5. as the described vaccine of claim 1-4, wherein said vaccine also comprises 3 type polioviruses of deactivation, and its dosage is 8-20D antigen unit, 9-19D antigen unit, 10-18D antigen unit, 11-17D antigen unit, 12-16D antigen unit, or 13-15D antigen unit; For example about or accurate 14D antigen unit.
6. as the described vaccine of claim 1-4, wherein said vaccine also comprises 3 type polioviruses of deactivation, and its amount is every 0.5mL8-20D antigen unit, 9-19D antigen unit, 10-18D antigen unit, 11-17D antigen unit, 12-16D antigen unit, or 13-15D antigen unit; About or the accurate 14D of for example every 0.5mL antigen unit.
7. as claim 5 or 6 described vaccines, the dosage of 3 type polioviruses of wherein said deactivation is greater than 8 and less than 20D antigen unit.
8. as claim 5 or 6 described vaccines, the amount of 3 type polioviruses of wherein said deactivation is that every 0.5mL is greater than 8 and less than 20D antigen unit.
9. IPV vaccine that comprises 3 type polioviruses of deactivation, wherein the dosage of 3 type polioviruses of deactivation is greater than 8 and less than 20D antigen unit, 9-19D antigen unit, 10-18D antigen unit, 11-17D antigen unit, 12-16D antigen unit, or 13-15D antigen unit; For example about or accurate 14D antigen unit.
10. IPV vaccine that comprises 3 type polioviruses of deactivation, wherein the amount of 3 type polioviruses of deactivation is that every 0.5mL is greater than 8 and less than 20D antigen unit, 9-19D antigen unit, 10-18D antigen unit, 11-17D antigen unit, 12-16D antigen unit, or 13-15D antigen unit; About or the accurate 14D of for example every 0.5mL antigen unit.
11. as claim 9 or 10 described vaccines, wherein said vaccine also comprises 1 type poliovirus of deactivation, its dosage is 10-20D antigen unit, 11-19D antigen unit, 12-18D antigen unit, 13-17D antigen unit, 14-16D antigen unit; For example about or accurate 15D antigen unit.
12. as claim 9 or 10 described vaccines, wherein said vaccine also comprises 1 type poliovirus of deactivation, its amount is every 0.5mL10-20D antigen unit, 11-19D antigen unit, 12-18D antigen unit, 13-17D antigen unit, 14-16D antigen unit; About or the accurate 15D of for example every 0.5mL antigen unit.
13. as the described vaccine of claim 1-12, wherein said vaccine also comprises 2 type polioviruses of deactivation, its dosage is 2-4D antigen unit.
14. as the described vaccine of claim 1-12, wherein said vaccine also comprises 2 type polioviruses of deactivation, its amount is every 0.5mL2-4D antigen unit.
15. as claim 13 or 14 described vaccines, the dosage of 2 type polioviruses of wherein said deactivation is greater than 2D antigen unit and less than 4D antigen unit, or its dosage is about or accurate 3D antigen unit.
16. as claim 13 or 14 described vaccines, the amount of 2 type polioviruses of wherein said deactivation be every 0.5mL greater than 2D antigen unit and less than 4D antigen unit, or its amount is for the about or accurate 3D of every 0.5mL antigen unit.
17. as the described vaccine of claim 1-16, wherein compare with the vaccine of the 1 type IPV that comprises 40D antigen unit, its relative effectivenes value is at least 0.85,0.9,0.95 or 1.
18. as the described vaccine of claim 1-17, wherein compare with the vaccine of the 2 type IPV that comprise 8D antigen unit, its relative effectivenes value is at least 0.85,0.9,0.95 or 1.
19. as the described vaccine of claim 1-18, wherein compare with the vaccine of the 3 type IPV that comprise 32D antigen unit, its relative effectivenes value is at least 0.85,0.9,0.95 or 1.
20. as the described vaccine of claim 1-19, wherein said vaccine also comprises diphtheria toxoid, its optional being adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture.
21. as the described vaccine of claim 1-20, wherein said vaccine also comprises tetanus toxoid, its optional being adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture.
22. as the described vaccine of claim 1-21, wherein said vaccine also comprises the whole cell pertussis bacillus (Bordetella pertussis) of deactivation, it is substantially free of thimerosal, optional being adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture.
23. as the described vaccine of claim 1-21, wherein said vaccine also comprises two or more acellular pertussis components (Pa) (DT-Pa (PT) for example, thread hemagglutinin (FHA) and pertactin (PRN)), its optional being adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture.
24. a DTP vaccine, it is substantially free of thimerosal, and comprises one or more IPV components, and described IPV component is selected from;
A.1 type IPV, its dosage is 10-36D antigen unit, 11-32D antigen unit, 12-28D antigen unit, 13-24D antigen unit, 14-20D antigen unit or 15-19D antigen unit; About or accurate 18D antigen unit;
B.2 type IPV, its dosage is 2-7D antigen unit, 3-6D antigen unit, or 4-5D antigen unit; With
C.3 type IPV, its dosage is 8-29D antigen unit, 9-26D antigen unit, 10-23D antigen unit, 11-20D antigen unit, 12-17D antigen unit, or 13-14D antigen unit.
25. vaccine as claimed in claim 24, described vaccine comprises 1 type poliovirus of deactivation, its dosage is 10-36D antigen unit, 11-32D antigen unit, 12-28D antigen unit, 13-24D antigen unit, 14-20D antigen unit or 15-19D antigen unit, about or accurate 18D antigen unit.
26. as claim 24 or 25 described vaccines, described vaccine comprises 2 type polioviruses of deactivation, its dosage is 2-7D antigen unit, 3-6D antigen unit, or 4-5D antigen unit.
27. as the described vaccine of claim 24-26, described vaccine comprises 3 type polioviruses of deactivation, its dosage is 8-29D antigen unit, 9-26D antigen unit, 10-23D antigen unit, 11-20D antigen unit, 12-17D antigen unit, or 13-14D antigen unit.
28. as the described vaccine of claim 1-27, it comprises the 1 type poliovirus that is adsorbed onto the deactivation on aluminium hydroxide or aluminum phosphate or the two the mixture.
29. as the described vaccine of claim 1-28, it comprises the 2 type polioviruses that are adsorbed onto the deactivation on aluminium hydroxide or aluminum phosphate or the two the mixture.
30. as the described vaccine of claim 1-29, it comprises the 3 type polioviruses that are adsorbed onto the deactivation on aluminium hydroxide or aluminum phosphate or the two the mixture.
31. as the described vaccine of claim 1-30, described vaccine comprises 1, the 2 and 3 type IPV that are adsorbed onto on the aluminum salt.
32. as the described vaccine of claim 1-31, it comprises 1, the 2 and 3 type IPV that are adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture.
33. as the described vaccine of claim 1-32, it comprises the optional diphtheria toxoid that is adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture.
34. as the described vaccine of claim 1-33, it comprises the optional tetanus toxoid that is adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture.
35. as the described vaccine of claim 1-34, it comprises optional whole cell pertussis bacillus or two or more acellular pertussis components (Pa) (for example PT, FHA and PRN) that is adsorbed onto the deactivation on the aluminum phosphate.
36. as the described vaccine of claim 1-35, wherein said vaccine also comprises hepatitis B surface antigen, it is substantially free of thimerosal, optional being adsorbed onto on the aluminum phosphate.
37. as the described vaccine of claim 1-36, wherein said vaccine also comprises the conjugate of carrier protein and Type B hemophilus influenza (Hib) capsular saccharides, its optional being adsorbed onto on the aluminum phosphate or not is adsorbed onto on the adjuvant.
38. as the described vaccine of claim 1-37, wherein said vaccine also comprises one or more conjugates of carrier protein and bacterial capsule sugar, described antibacterial is selected from A type meningococcus (Neisseria meningitidis), C type meningococcus, W type meningococcus and Y type meningococcus, described conjugate is optional to be adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture or not to be adsorbed onto on the adjuvant.
39. as the described vaccine of claim 1-38, the MenB capsular saccharides that wherein said vaccine also comprises Type B meningococcus (MenB) outer membrane vesicles or LOS or puts together, or derivatives thereof, it is optional to be adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture or not to be adsorbed onto on the adjuvant.
40. as the described vaccine of claim 1-39, wherein said vaccine also comprises salmonella typhi (Salmonella typhi) the Vi sugar of puting together with carrier protein, and it is optional to be adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture or not to be adsorbed onto on the adjuvant.
41. as the described vaccine of claim 1-40, wherein said vaccine also comprises hav antigen, its optional being adsorbed onto on aluminium hydroxide or aluminum phosphate or the two the mixture.
42. as the described vaccine of claim 1-41, wherein said vaccine comprises DT, its amount is 5-50 in every 0.5mL dosage, about or accurate 7.5Lf of 7-30Lf or 25Lf.
43. as the described vaccine of claim 1-41, wherein said vaccine comprises DT, its amount in every 0.5mL dosage less than 5Lf, or the about or accurate 2Lf of 1-4Lf.
44. as the described vaccine of claim 1-43, wherein said vaccine comprises TT, its amount is 2.5-30Lf in every 0.5mL dosage, 3-20Lf, the accurate or about 10Lf of 5-15Lf.
45. as the described vaccine of claim 1-44, wherein said vaccine comprises Pa, it comprises 2-50 μ g in every 0.5mL dosage, 5-40 μ g, the PT of the accurate or about 25 μ g of 10-30 μ g.
46. as the described vaccine of claim 1-45, wherein said vaccine comprises Pa, it comprises in every 0.5mL dosage accurate or about 2.5 or the PT of 8 μ g.
47. as the described vaccine of claim 1-46, wherein said vaccine comprises Pa, it comprises 2-50 μ g in every 0.5mL dosage, 5-40 μ g, the FHA of the accurate or about 25 μ g of 10-30 μ g
48. as the described vaccine of claim 1-47, wherein said vaccine comprises Pa, it comprises in every 0.5mL dosage accurate or about 2.5 or the FHA of 8 μ g.
49. as the described vaccine of claim 1-48, wherein said vaccine comprises Pa, it comprises 0.5-20 μ g in every 0.5mL dosage, 0.8-15 μ g, the PRN of the accurate or about 8 μ g of 2-10 μ g.
50. as the described vaccine of claim 1-49, wherein said vaccine comprises Pa, it comprises in every 0.5mL dosage accurate or about 0.8 or the PRN of 2.5 μ g.
51. as the described vaccine of claim 1-44, wherein said vaccine comprises Pw, its amount is every 0.5mL dosage 5-50IOU, 7-40IOU, 9-35IOU, 11-30IOU, 13-25IOU, the about or accurate 20IOU of 15-21IOU.
52. as the described vaccine of claim 1-51, wherein said vaccine comprises HB, its amount is for every 0.5mL5-20 μ g, 8-15 μ g is about or accurate 10 μ g.
53. as the described vaccine of claim 1-52, wherein said vaccine comprises Hib, its amount is for every 0.5mL dosage 5-20 μ g, 8-15 μ g is about or accurate 10 μ g.
54. as the described vaccine of claim 1-52, wherein said vaccine comprises Hib, its amount is every 0.5mL dosage 1-6 μ g, 2-4 μ g, about or accurate 2.5 μ g.
55. as the described vaccine of claim 1-54, wherein said vaccine also comprises one or more adjuvants, described adjuvant is selected from: aluminum salt such as aluminium hydroxide or aluminum phosphate; calcium salt; iron salt or zinc salt, the insoluble suspension of acidylate tyrosine or acidylate sugar, the sugar of cation or anionic derivative; polyphosphazene, biodegradable microsphere, monophosphoryl lipid A (MPL); the lipoid A derivant of perform toxic attenuation, 3-O-deacylated tRNA MPL, quil A; saponin, QS21, tocopherol; AS-2; the CpG oligonucleotide, bioadhesive polymer, mucomembranous adhesion agent; microgranule; liposome, polyoxyethylene ether preparation, polyoxyethylene ester formulation; muramyl peptide; imidazoquinolie compounds, interleukin, M-CSF (M-CSF); tumor necrosis factor (TNF), granulocyte and M-CSF (GM-CSF).
56. vaccine as claimed in claim 55, wherein said adjuvant are preferred TH1 inducers.
57. a syringe that comprises vaccine, its comprise dose as each described vaccine among the claim 1-56.
58. a bottle that comprises vaccine, its comprise 1 time or 2 times dosage as each described vaccine among the claim 1-56.
59. a method for preparing as the described vaccine of claim 1-58, described method comprises the step with IPV and pharmaceutically acceptable mixed with excipients.
60. comprising to its people of needs, a prevention or the method that the treatment poliovirus infects and optional clostridium tetani (Clostridium tetani), diphtheria corynebacterium (Corynebacterium diphtheria) and/or bordetella pertussis (Clostridium tetani) infects, described method use described vaccine as claim 1-58.
61. a prevention or the method that the treatment poliovirus infects and optional clostridium tetani (Clostridium tetani), diphtheria corynebacterium (Corynebacterium diphtheria) and/or bordetella pertussis (Clostridium tetani) infects, described method is included in the initial immunity scheme in 1 year of life is needed its people to use the described vaccine as claim 1-58.
62. a prevention or treatment poliovirus, clostridium tetani, diphtheria corynebacterium and bordetella pertussis infect and one or more the method for optional hepatitis B, b type hemophilus influenza, A type meningococcus, C type meningococcus, W type meningococcus, Y type meningococcus, Type B meningococcus, salmonella typhi and hepatitis A in infecting, described method comprises uses the described vaccine as claim 24-58.
63. be used for preventing the purposes of the medicine of the disease that causes by poliovirus and optional clostridium tetani, diphtheria corynebacterium and/or bordetella pertussis in preparation as the described vaccine of claim 1-58.
64. as the described vaccine of claim 24-58 preparation be used for preventing infecting by poliovirus, clostridium tetani, diphtheria corynebacterium and bordetella pertussis and the medicine of one or more diseases that cause that optional hepatitis B, b type hemophilus influenza, A type meningococcus, C type meningococcus, W type meningococcus, Y type meningococcus, Type B meningococcus, salmonella typhi and hepatitis A infects in purposes.
65. comprise the purposes of the medicine that the vaccine of the IPV standard dose of 25-50% is used for guarding against poliomyelities in preparation, wherein said vaccine is realized at least 0.85,0.9,0.95 or 1 relative effectivenes value.
66. as the described purposes of claim 65, wherein said vaccine is arbitrary described vaccine among the claim 1-58.
67. a test kit, described test kit comprise first container, second container and the 3rd optional container, wherein:
A) first container comprises
1. as the described IPV vaccine of claim 1-58;
2. as the described diphtheria toxoid of claim 20-58;
3. as the described tetanus toxoid of claim 21-58;
4. as the whole cell pertussis bacillus (Pw) of the described deactivation of claim 22-58, or as the described acellular pertussis components of claim 23-58 (Pa);
5. optional as the described hepatitis B surface antigen of claim 36-58;
6. Ren Xuan conjugate as described carrier protein of claim 37-58 and Type B hemophilus influenza capsular saccharides,
B) second container comprises
1. optional as the described hepatitis B surface antigen of claim 36-58;
2. Ren Xuan conjugate as described carrier protein of claim 37-58 and Type B hemophilus influenza capsular saccharides;
3. optional as in the described MenA of claim 38-58, MenC, MenW or the MenY conjugate one or more;
4. optional as the described MenB outer membrane vesicles of claim 39-58 or LOS or MenB capsular saccharides conjugate;
5. optional as the described salmonella typhi Vi of claim 40-58 conjugate;
It is 6. optional as the described hav antigen of claim 41-58,
C) Ren Xuan the 3rd container comprises
1. optional as the described hepatitis B surface antigen of claim 36-58;
2. Ren Xuan conjugate as described carrier protein of claim 37-58 and Type B hemophilus influenza capsular saccharides;
3. optional as in the described MenA of claim 38-58, MenC, MenW or the MenY conjugate one or more;
4. optional as the described MenB outer membrane vesicles of claim 39-58 or LOS or MenB capsular saccharides conjugate;
5. optional as the described salmonella typhi Vi of claim 40-58 conjugate;
6. optional as the described hav antigen of claim 41-58.
68. as the described test kit of claim 67, wherein hepatitis B surface antigen is present in described first container.
69. as the described test kit of claim 67, wherein hepatitis B surface antigen is present in described second container.
70. as the described test kit of claim 67, wherein hepatitis B surface antigen is present in described the 3rd container.
71. as the described test kit of claim 67-70, wherein the conjugate of carrier protein and Type B hemophilus influenza capsular saccharides is present in described first container.
72. as the described test kit of claim 67-70, wherein the conjugate of carrier protein and Type B hemophilus influenza capsular saccharides is present in described second container.
73. as the described test kit of claim 67-70, wherein the conjugate of carrier protein and Type B hemophilus influenza capsular saccharides is present in described the 3rd container.
74. as the described test kit of claim 67-73, wherein one or more in MenA, MenC, MenW or the MenY conjugate are present in described second container.
75. as the described test kit of claim 67-73, wherein one or more in MenA, MenC, MenW or the MenY conjugate are present in described the 3rd container.
76. as the described test kit of claim 67-75, wherein MenB outer membrane vesicles or LOS or MenB conjugate are present in described second container.
77. as the described test kit of claim 67-75, wherein MenB outer membrane vesicles or LOS or MenB conjugate are present in described the 3rd container.
78. as the described test kit of claim 67-77, wherein salmonella typhi Vi conjugate is present in described second container.
79. as the described test kit of claim 67-77, wherein salmonella typhi Vi conjugate is present in described the 3rd container.
80. as the described test kit of claim 67-79, wherein hav antigen is present in described second container.
81. as the described test kit of claim 67-79, wherein hav antigen is present in described the 3rd container.
82. as the described test kit of claim 67-81, it is provided for using a series of description of described vaccine.
83. the purposes of the medicine that is used for guarding against poliomyelities in preparation as the described test kit of claim 67-82.
84. a method of using as the described test kit of claim 67-82, wherein the vaccine in all containers is used when once seeking medical advice together simultaneously.
85. as the described vaccine of claim 1-84, method, purposes or test kit, if wherein there is 1 type IPV, then described 1 type IPV comes from the Mahoney strain.
86. as the described vaccine of claim 1-85, method, purposes or test kit, if wherein there are 2 type IPV, then described 2 type IPV come from the MEF-1 strain.
87. as the described vaccine of claim 1-86, method, purposes or test kit, if wherein there are 3 type IPV, then described 3 type IPV come from the Saukett strain.
CN200780041465.XA 2006-09-07 2007-09-07 Vaccine Active CN101534855B (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0617602.8 2006-09-07
GBGB0617602.8A GB0617602D0 (en) 2006-09-07 2006-09-07 Vaccine
GB0625593A GB0625593D0 (en) 2006-12-21 2006-12-21 Vaccine
GB0625593.9 2006-12-21
PCT/EP2007/059390 WO2008028956A1 (en) 2006-09-07 2007-09-07 Vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201310079459.0A Division CN103585624A (en) 2006-09-07 2007-09-07 Vaccine

Publications (2)

Publication Number Publication Date
CN101534855A true CN101534855A (en) 2009-09-16
CN101534855B CN101534855B (en) 2017-08-01

Family

ID=37232508

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA2007800414575A Pending CN101534854A (en) 2006-09-07 2007-09-07 Vaccine
CN200780041465.XA Active CN101534855B (en) 2006-09-07 2007-09-07 Vaccine

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA2007800414575A Pending CN101534854A (en) 2006-09-07 2007-09-07 Vaccine

Country Status (5)

Country Link
CN (2) CN101534854A (en)
ES (1) ES2365557T5 (en)
GB (1) GB0617602D0 (en)
UA (2) UA97376C2 (en)
ZA (2) ZA200901530B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2097102E (en) 2006-09-07 2012-08-03 Glaxosmithkline Biolog Sa Combination vaccine having reduced polio virus antigen quantities
CN112138155B (en) * 2019-06-28 2022-04-12 怡道生物科技(苏州)有限公司 Compound adjuvant system and method for preparing adjuvant
CN111467488B (en) * 2020-04-17 2023-09-01 内蒙古必威安泰生物科技有限公司 Water-soluble composite immunoadjuvant and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69319728T2 (en) * 1992-05-23 1999-02-04 Smithkline Beecham Biolog Combined vaccines that contain hepatitis B surface antigen and other antigens
CA2259415A1 (en) * 1996-07-02 1998-01-08 Connaught Laboratories Limited Multivalent dtp-polio vaccines
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition

Also Published As

Publication number Publication date
CN101534854A (en) 2009-09-16
ZA200901530B (en) 2010-05-26
ZA200901592B (en) 2010-06-30
UA97376C2 (en) 2012-02-10
ES2365557T3 (en) 2011-10-06
GB0617602D0 (en) 2006-10-18
CN101534855B (en) 2017-08-01
ES2365557T5 (en) 2016-12-07
UA95810C2 (en) 2011-09-12

Similar Documents

Publication Publication Date Title
CN103585624A (en) Vaccine
RU2641969C2 (en) Multiple vaccination including serogroup c meningococci
US8551451B2 (en) Combination vaccine with acellular pertussis
US20100226937A1 (en) Combination vaccines with 1-hydroxy-2-phenoxyethane preservative
BRPI0618359A2 (en) manufacture of vaccines containing surface hepatitis B virus antigen and surfactant
CA2601676A1 (en) Combination vaccines with whole cell pertussis antigen
CA2741393A1 (en) Combination vaccine with whole cell pertussis
CN101534855A (en) Vaccine

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant